{
  "_meta": {
    "description": "Vaccine development pipeline — candidate-level records. Bulk rows auto-grouped from ClinicalTrials.gov BIOLOGICAL vaccine trials; hand-curated Tier 1/3 rows retained for filing/approval edge cases. Company timelines ≠ registry dates. Includes FDA CBER licensed/recent vaccine approvals (Tier 3).",
    "lastUpdated": "2026-07-10",
    "schemaVersion": "1.1.0",
    "updateCadence": "Re-run: python fetch_vaccine_pipeline_from_ctgov.py (weekly/monthly). Quarterly review of company pipeline pages and VRBPAC for filing/approval status.",
    "ctgovFetch": {
      "fetchedAt": "2026-07-10",
      "rawTrialsAfterFilter": 1856,
      "groups": 1670,
      "autoCandidatesKept": 300,
      "curatedRetained": 8,
      "totalPublished": 281
    },
    "fdaApprovalsFetch": {
      "fetchedAt": "2026-07-10",
      "fdaRowsMerged": 40,
      "sources": [
        "https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states",
        "https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biological-approvals-year"
      ],
      "note": "Regulator-confirmed US vaccine licenses from FDA CBER year BLA pages + licensed list + hand checklist (2023-2026 focus)"
    }
  },
  "candidates": [
    {
      "candidateId": "mrna-1010",
      "name": "mRNA-1010",
      "developer": "Moderna",
      "targetDisease": "Seasonal influenza",
      "platform": "mRNA",
      "currentStage": "regulatory_submission_filed",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "regulatory_submission_filed",
          "date": "2026-01",
          "dateType": "company_estimate",
          "notes": "Company-reported filing; confirm against FDA docket before treating as regulator-confirmed"
        },
        {
          "jurisdiction": "EU",
          "status": "regulatory_submission_filed",
          "date": "2026-01",
          "dateType": "company_estimate"
        },
        {
          "jurisdiction": "Canada",
          "status": "regulatory_submission_filed",
          "date": "2026-01",
          "dateType": "company_estimate"
        },
        {
          "jurisdiction": "Australia",
          "status": "regulatory_submission_filed",
          "date": "2026-01",
          "dateType": "company_estimate"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "Regulatory decision(s) pending across filed jurisdictions (company projection)",
      "sourceType": "company disclosure (Tier 1)",
      "sourceCitation": {
        "label": "Moderna Analyst Day pipeline update (press summary)",
        "url": "https://www.biospace.com/press-releases/moderna-analyst-day-highlights-pipeline-progress-and-business-strategy-updates",
        "date": "2025-11"
      },
      "lastCompanyUpdate": "2025-11-21",
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Company-projected timelines frequently slip; treat next-milestone dates as company estimates."
    },
    {
      "candidateId": "mrna-1083",
      "name": "mRNA-1083",
      "developer": "Moderna",
      "targetDisease": "Seasonal influenza + COVID-19 (combination)",
      "platform": "mRNA",
      "currentStage": "regulatory_submission_filed",
      "jurisdictionStatus": [
        {
          "jurisdiction": "EU",
          "status": "under_regulatory_review",
          "date": "under EMA review",
          "dateType": "company_estimate"
        },
        {
          "jurisdiction": "Canada",
          "status": "regulatory_submission_filed",
          "date": "2025",
          "dateType": "company_estimate"
        },
        {
          "jurisdiction": "US",
          "status": "regulatory_submission_withdrawn_pending_refiling",
          "date": "withdrawn May 2025",
          "dateType": "company_estimate",
          "notes": "Voluntary US withdrawal pending FDA guidance; not a global discontinuation"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US refiling pending FDA guidance; EU/Canada decisions pending (company projection)",
      "sourceType": "company disclosure (Tier 1)",
      "sourceCitation": {
        "label": "Moderna Analyst Day / pipeline disclosures",
        "url": "https://www.biospace.com/press-releases/moderna-analyst-day-highlights-pipeline-progress-and-business-strategy-updates",
        "date": "2025-11"
      },
      "lastCompanyUpdate": "2025-11-21",
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Illustrates multi-jurisdiction status: filed/under review in some regions while US pathway was withdrawn pending refiling."
    },
    {
      "candidateId": "vax-31-adult",
      "name": "VAX-31 (adult)",
      "developer": "Vaxcyte",
      "targetDisease": "Invasive pneumococcal disease (31-valent conjugate)",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "phase_3",
          "date": "2026",
          "dateType": "company_estimate"
        }
      ],
      "trialSubEntries": [
        {
          "trialName": "OPUS-1",
          "comparator": "standard-of-care PCVs",
          "expectedReadout": "Q4 2026",
          "population": "Adults",
          "status": "recruiting / ongoing (verify on ClinicalTrials.gov)"
        },
        {
          "trialName": "OPUS-2",
          "comparator": "concomitant influenza vaccine, ages 50+",
          "expectedReadout": "TBD",
          "population": "Adults 50+",
          "status": "planned / ongoing (verify)"
        },
        {
          "trialName": "OPUS-3",
          "comparator": "prior pneumococcal vaccine recipients",
          "expectedReadout": "TBD",
          "population": "Previously vaccinated adults",
          "status": "planned / ongoing (verify)"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "Topline data from OPUS-1 (company: Q4 2026); planned BLA submission to follow if positive",
      "sourceType": "company SEC filing (Tier 1)",
      "sourceCitation": {
        "label": "Vaxcyte SEC exhibit / investor disclosure",
        "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/pcvx-20260224xexx991.htm",
        "date": "2026"
      },
      "lastCompanyUpdate": "2026-02",
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "One candidate program with multiple concurrent Phase 3 sub-studies — not three separate candidates."
    },
    {
      "candidateId": "vla15",
      "name": "VLA15",
      "developer": "Valneva / Pfizer",
      "targetDisease": "Lyme disease",
      "platform": "Protein subunit (OspA)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "phase_3",
          "date": "H1 2026 field efficacy readout (company)",
          "dateType": "company_estimate"
        },
        {
          "jurisdiction": "EU",
          "status": "phase_3",
          "date": "H1 2026 field efficacy readout (company)",
          "dateType": "company_estimate"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "VALOR Phase 3 field efficacy results (company: H1 2026); BLA/MAA planned if positive",
      "sourceType": "company disclosure (Tier 1)",
      "sourceCitation": {
        "label": "Valneva FY results disclosure (SEC 6-K summary path)",
        "url": "https://www.sec.gov/Archives/edgar/data/1836564/000162828026019159/a2026_03x18xfyx2025xresult.htm",
        "date": "2026-03"
      },
      "lastCompanyUpdate": "2026-03",
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Most advanced Lyme vaccine candidate in late clinical development; targets multiple prevalent Borrelia serotypes (company materials)."
    },
    {
      "candidateId": "ixchiq",
      "name": "IXCHIQ",
      "developer": "Valneva",
      "targetDisease": "Chikungunya",
      "platform": "Live attenuated",
      "currentStage": "approved_restricted_or_suspended",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved_then_suspended",
          "date": "FDA suspended license post-approval — verify current FDA status before clinical use",
          "dateType": "regulator_confirmed",
          "notes": "Post-approval regulatory action; status can change — check live FDA communications"
        },
        {
          "jurisdiction": "EU",
          "status": "approved_with_updated_guidance",
          "date": "EMA revised guidance on use in elderly populations",
          "dateType": "regulator_confirmed"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "Follow FDA/EMA communications for current authorization status and age restrictions",
      "sourceType": "regulatory tracking (Tier 3) + company",
      "sourceCitation": {
        "label": "FDA vaccines licensed / safety communications (verify live)",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states",
        "date": "2026"
      },
      "additionalCitations": [
        {
          "label": "EMA — search product information for IXCHIQ / chikungunya",
          "url": "https://www.ema.europa.eu/en/medicines",
          "date": "2026"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Required edge case: approval is not always terminal. A licensed vaccine can be suspended or restricted post-approval. Re-verify live FDA/EMA status before publishing clinical implications."
    },
    {
      "candidateId": "mrna-1345-rsv",
      "name": "mRNA-1345 (mRESVIA context / next-gen RSV programs)",
      "developer": "Moderna",
      "targetDisease": "RSV",
      "platform": "mRNA",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2024+",
          "dateType": "regulator_confirmed",
          "notes": "mRESVIA approved for indicated adult groups; pipeline may include expanded indications — check current label"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "Label expansions / seasonal updates as disclosed; see licensed RSV page for post-licensure safety",
      "sourceType": "regulatory (Tier 3) + company",
      "sourceCitation": {
        "label": "FDA vaccines licensed for use in the United States",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states",
        "date": "2026"
      },
      "lastCompanyUpdate": "2025",
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "When a candidate is approved, the site loop closes to the licensed vaccine evidence page (rsv-vaccine.html)."
    },
    {
      "candidateId": "pfizer-dual-flu-covid",
      "name": "Influenza + COVID combination candidates (Pfizer/BioNTech family)",
      "developer": "Pfizer / BioNTech",
      "targetDisease": "Seasonal influenza + COVID-19 (combination)",
      "platform": "mRNA",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "phase_3",
          "date": "verify current phase on ClinicalTrials.gov",
          "dateType": "unknown"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "Phase 3 readouts and potential regulatory filings (company-dependent; verify latest 10-Q/investor materials)",
      "sourceType": "company disclosure (Tier 1) + ClinicalTrials.gov (Tier 2)",
      "sourceCitation": {
        "label": "ClinicalTrials.gov — search influenza COVID combination vaccine",
        "url": "https://clinicaltrials.gov/",
        "date": "2026"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Program-level placeholder: multiple NCT records may map to this candidate family — group trials rather than listing raw NCT rows as separate products."
    },
    {
      "candidateId": "novavax-flu-covid",
      "name": "COVID-Influenza Combination (CIC) — Novavax",
      "developer": "Novavax",
      "targetDisease": "Seasonal influenza + COVID-19 (combination)",
      "platform": "Protein nanoparticle + Matrix-M",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "phase_3",
          "date": "verify on ClinicalTrials.gov / company pipeline",
          "dateType": "company_estimate"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "Phase 3 data and potential regulatory path (company projection — verify latest filings)",
      "sourceType": "company disclosure (Tier 1)",
      "sourceCitation": {
        "label": "Novavax pipeline / investor materials (verify live)",
        "url": "https://www.novavax.com/",
        "date": "2026"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html"
    },
    {
      "candidateId": "fda-abrysvo",
      "name": "ABRYSVO",
      "developer": "Pfizer Inc.",
      "targetDisease": "RSV",
      "platform": "See FDA product page / label",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2023-05-31",
          "dateType": "regulator_confirmed",
          "notes": "FDA approval / licensure action (public FDA materials)"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — ABRYSVO",
        "url": "https://www.fda.gov/vaccines-blood-biologics/abrysvo",
        "date": "2023-05-31"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). RSV prefusion F vaccine; older adult and maternal indications (see label for current ages). May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-arexvy",
      "name": "AREXVY",
      "developer": "GlaxoSmithKline Biologicals",
      "targetDisease": "RSV",
      "platform": "See FDA product page / label",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2023-05-03",
          "dateType": "regulator_confirmed",
          "notes": "FDA approval / licensure action (public FDA materials)"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — AREXVY",
        "url": "https://www.fda.gov/vaccines-blood-biologics/arexvy",
        "date": "2023-05-03"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). First FDA-approved RSV vaccine for older adults (initial approval May 2023); later age/risk expansions via supplements. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-capvaxive",
      "name": "CAPVAXIVE",
      "developer": "See FDA listing",
      "targetDisease": "Pneumococcal disease",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2024",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — CAPVAXIVE",
        "url": "https://www.fda.gov/vaccines-blood-biologics/capvaxive",
        "date": "2024"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). Linked from FDA 2024 biological license application approvals page. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-comirnaty",
      "name": "COMIRNATY",
      "developer": "Pfizer-BioNTech",
      "targetDisease": "COVID-19",
      "platform": "See FDA product page / label",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2021-08-23",
          "dateType": "regulator_confirmed",
          "notes": "FDA approval / licensure action (public FDA materials)"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — COMIRNATY",
        "url": "https://www.fda.gov/vaccines-blood-biologics/comirnaty",
        "date": "2021-08-23"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). First fully licensed COVID-19 mRNA vaccine in US; subsequent seasonal formulations. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-covid-19-vaccine-adjuvanted",
      "name": "COVID-19 Vaccine, Adjuvanted",
      "developer": "See FDA listing",
      "targetDisease": "COVID-19",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — COVID-19 Vaccine, Adjuvanted",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/nuvaxovid",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-covid-19-vaccine-mrna",
      "name": "COVID-19 Vaccine, mRNA",
      "developer": "See FDA listing",
      "targetDisease": "COVID-19",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — COVID-19 Vaccine, mRNA",
        "url": "https://www.fda.gov/vaccines-blood-biologics/spikevax",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-cyfendus",
      "name": "CYFENDUS",
      "developer": "Emergent BioSolutions",
      "targetDisease": "Anthrax",
      "platform": "See FDA product page / label",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2023-07-20",
          "dateType": "regulator_confirmed",
          "notes": "FDA approval / licensure action (public FDA materials)"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — CYFENDUS",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/cyfendus",
        "date": "2023-07-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). Anthrax vaccine adsorbed, adjuvanted (post-exposure prophylaxis context). May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-chikungunya-vaccine-recombinant",
      "name": "Chikungunya Vaccine, Recombinant",
      "developer": "See FDA listing",
      "targetDisease": "Chikungunya",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Chikungunya Vaccine, Recombinant",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vimkunya",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-dengue-tetravalent-vaccine-live",
      "name": "Dengue Tetravalent Vaccine, Live",
      "developer": "See FDA listing",
      "targetDisease": "Dengue",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Dengue Tetravalent Vaccine, Live",
        "url": "https://www.fda.gov/vaccines-blood-biologics/dengvaxia",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-diphtheria-and-tetanus-toxoids-and-acellular-pertussis-a",
      "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Mening",
      "developer": "See FDA listing",
      "targetDisease": "Meningococcal disease",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaxelis",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-ebola-zaire-vaccine-live",
      "name": "Ebola Zaire Vaccine, Live",
      "developer": "See FDA listing",
      "targetDisease": "Ebola",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Ebola Zaire Vaccine, Live",
        "url": "https://www.fda.gov/vaccines-blood-biologics/ervebo",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-hepatitis-b-vaccine-recombinant",
      "name": "Hepatitis B Vaccine (Recombinant)",
      "developer": "See FDA listing",
      "targetDisease": "Hepatitis B",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Hepatitis B Vaccine (Recombinant)",
        "url": "https://www.fda.gov/vaccines-blood-biologics/prehevbrio",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hepatitis-b-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-hepatitis-b-vaccine-recombinant-adjuvanted",
      "name": "Hepatitis B Vaccine (Recombinant), Adjuvanted",
      "developer": "See FDA listing",
      "targetDisease": "Hepatitis B",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Hepatitis B Vaccine (Recombinant), Adjuvanted",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/heplisav-b",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hepatitis-b-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-human-papillomavirus-9-valent-vaccine-recombinant",
      "name": "Human Papillomavirus 9-valent Vaccine, Recombinant",
      "developer": "See FDA listing",
      "targetDisease": "HPV",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Human Papillomavirus 9-valent Vaccine, Recombinant",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil-9",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-ixchiq",
      "name": "IXCHIQ",
      "developer": "Valneva Austria GmbH",
      "targetDisease": "Chikungunya",
      "platform": "See FDA product page / label",
      "currentStage": "approved_restricted_or_suspended",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved_restricted_or_suspended",
          "date": "2023-11-09",
          "dateType": "regulator_confirmed",
          "notes": "FDA approval / licensure action (public FDA materials)"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — IXCHIQ",
        "url": "https://www.fda.gov/vaccines-blood-biologics/ixchiq",
        "date": "2023-11-09"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). First chikungunya vaccine licensed in US; later subject to post-approval safety actions — verify current FDA status. May also have later supplements (strain updates, age expansions); see product page. Check live FDA communications for current license status (post-approval actions possible)."
    },
    {
      "candidateId": "fda-influenza-a-h5n1-monovalent-vaccine-adjuvanted",
      "name": "Influenza A (H5N1) Monovalent Vaccine, Adjuvanted",
      "developer": "See FDA listing",
      "targetDisease": "Influenza",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Influenza A (H5N1) Monovalent Vaccine, Adjuvanted",
        "url": "https://www.fda.gov/vaccines-blood-biologics/audenz",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-influenza-vaccine",
      "name": "Influenza Vaccine",
      "developer": "See FDA listing",
      "targetDisease": "Influenza",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Influenza Vaccine",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/flucelvax-quadrivalent",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-influenza-vaccine-quadrivalent",
      "name": "Influenza Vaccine (Quadrivalent)",
      "developer": "See FDA listing",
      "targetDisease": "Influenza",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Influenza Vaccine (Quadrivalent)",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/flublok-quadrivalent",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-influenza-vaccine-trivalent",
      "name": "Influenza Vaccine (Trivalent)",
      "developer": "See FDA listing",
      "targetDisease": "Influenza",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Influenza Vaccine (Trivalent)",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/flublok",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-influenza-vaccine-adjuvanted",
      "name": "Influenza Vaccine, Adjuvanted",
      "developer": "See FDA listing",
      "targetDisease": "Influenza",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Influenza Vaccine, Adjuvanted",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/fluad",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-influenza-virus-vaccine-trivalent-types-a-and-b",
      "name": "Influenza Virus Vaccine(Trivalent, Types A and B)",
      "developer": "See FDA listing",
      "targetDisease": "Influenza",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Influenza Virus Vaccine(Trivalent, Types A and B)",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/flucelvax",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-mnexspike",
      "name": "MNEXSPIKE",
      "developer": "See FDA listing",
      "targetDisease": "COVID-19",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2025",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — MNEXSPIKE",
        "url": "https://www.fda.gov/vaccines-blood-biologics/mnexspike",
        "date": "2025"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). Linked from FDA 2025 biological license application approvals page. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-measles-mumps-and-rubella-vaccine-live",
      "name": "Measles, Mumps and Rubella Vaccine, Live",
      "developer": "See FDA listing",
      "targetDisease": "Measles / Mumps / Rubella",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Measles, Mumps and Rubella Vaccine, Live",
        "url": "https://www.fda.gov/vaccines-blood-biologics/priorix",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "mmr-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-meningococcal-group-b-vaccine",
      "name": "Meningococcal Group B Vaccine",
      "developer": "See FDA listing",
      "targetDisease": "Meningococcal disease",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Meningococcal Group B Vaccine",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/trumenba",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-meningococcal-groups-a-b-c-w-and-y-vaccine",
      "name": "Meningococcal Groups A, B, C, W, and Y Vaccine",
      "developer": "See FDA listing",
      "targetDisease": "Meningococcal disease",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Meningococcal Groups A, B, C, W, and Y Vaccine",
        "url": "https://www.fda.gov/vaccines-blood-biologics/penmenvy",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-nuvaxovid",
      "name": "NUVAXOVID",
      "developer": "Novavax, Inc.",
      "targetDisease": "COVID-19",
      "platform": "See FDA product page / label",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2025",
          "dateType": "regulator_confirmed",
          "notes": "FDA approval / licensure action (public FDA materials)"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — NUVAXOVID",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/nuvaxovid",
        "date": "2025"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). Protein-based COVID-19 vaccine (US pathway evolved from EUA to licensure/seasonal updates — verify current strain formulation on FDA page). May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-penbraya",
      "name": "PENBRAYA",
      "developer": "See FDA listing",
      "targetDisease": "Meningococcal disease",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2023",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — PENBRAYA",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/penbraya",
        "date": "2023"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). Linked from FDA 2023 biological license application approvals page. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-penmenvy",
      "name": "PENMENVY",
      "developer": "See FDA listing",
      "targetDisease": "Meningococcal disease",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2025",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — PENMENVY",
        "url": "https://www.fda.gov/vaccines-blood-biologics/penmenvy",
        "date": "2025"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). Linked from FDA 2025 biological license application approvals page. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-priorix",
      "name": "PRIORIX",
      "developer": "GlaxoSmithKline Biologicals",
      "targetDisease": "Measles / Mumps / Rubella",
      "platform": "See FDA product page / label",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2022-06-03",
          "dateType": "regulator_confirmed",
          "notes": "FDA approval / licensure action (public FDA materials)"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — PRIORIX",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/priorix",
        "date": "2022-06-03"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "mmr-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). Second MMR vaccine licensed in the US (2022). May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-pneumococcal-15-valent-conjugate-vaccine",
      "name": "Pneumococcal 15-valent Conjugate Vaccine",
      "developer": "See FDA listing",
      "targetDisease": "Pneumococcal disease",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Pneumococcal 15-valent Conjugate Vaccine",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-pneumococcal-20-valent-conjugate-vaccine",
      "name": "Pneumococcal 20-valent Conjugate Vaccine",
      "developer": "See FDA listing",
      "targetDisease": "Pneumococcal disease",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Pneumococcal 20-valent Conjugate Vaccine",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-20",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-pneumococcal-21-valent-conjugate-vaccine",
      "name": "Pneumococcal 21-valent Conjugate Vaccine",
      "developer": "See FDA listing",
      "targetDisease": "Pneumococcal disease",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Pneumococcal 21-valent Conjugate Vaccine",
        "url": "https://www.fda.gov/vaccines-blood-biologics/capvaxive",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-respiratory-syncytial-virus-vaccine",
      "name": "Respiratory Syncytial Virus Vaccine",
      "developer": "See FDA listing",
      "targetDisease": "RSV",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Respiratory Syncytial Virus Vaccine",
        "url": "https://www.fda.gov/vaccines-blood-biologics/abrysvo",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-respiratory-syncytial-virus-vaccine-adjuvanted",
      "name": "Respiratory Syncytial Virus Vaccine, Adjuvanted",
      "developer": "See FDA listing",
      "targetDisease": "RSV",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Respiratory Syncytial Virus Vaccine, Adjuvanted",
        "url": "https://www.fda.gov/vaccines-blood-biologics/arexvy",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-spikevax",
      "name": "SPIKEVAX",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "COVID-19",
      "platform": "See FDA product page / label",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2022-01-31",
          "dateType": "regulator_confirmed",
          "notes": "FDA approval / licensure action (public FDA materials)"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — SPIKEVAX",
        "url": "https://www.fda.gov/vaccines-blood-biologics/spikevax",
        "date": "2022-01-31"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). Licensed COVID-19 mRNA vaccine; subsequent seasonal formulations. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-smallpox-and-monkeypox-vaccine-live-non-replicating",
      "name": "Smallpox and Monkeypox Vaccine, Live, Non-Replicating",
      "developer": "See FDA listing",
      "targetDisease": "Mpox / Smallpox",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Smallpox and Monkeypox Vaccine, Live, Non-Replicating",
        "url": "https://www.fda.gov/vaccines-blood-biologics/jynneos",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-vaxelis",
      "name": "VAXELIS",
      "developer": "MCM Vaccine Company",
      "targetDisease": "Diphtheria / Tetanus / Pertussis / Polio / Hib / HepB",
      "platform": "See FDA product page / label",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2018-12-21",
          "dateType": "regulator_confirmed",
          "notes": "FDA approval / licensure action (public FDA materials)"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — VAXELIS",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxelis",
        "date": "2018-12-21"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "dtap-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). Hexavalent combination (included as modern combination vaccine reference). May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-vimkunya",
      "name": "VIMKUNYA",
      "developer": "See FDA listing",
      "targetDisease": "Chikungunya",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2025",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — VIMKUNYA",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vimkunya",
        "date": "2025"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). Linked from FDA 2025 biological license application approvals page. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-zoster-vaccine-recombinant-adjuvanted",
      "name": "Zoster Vaccine Recombinant, Adjuvanted",
      "developer": "See FDA listing",
      "targetDisease": "Varicella / Zoster",
      "platform": "Licensed biologic (see FDA product page)",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "see FDA page",
          "dateType": "regulator_confirmed",
          "notes": "From FDA public vaccines/biologics approval materials"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — Zoster Vaccine Recombinant, Adjuvanted",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/shingrix",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). From FDA Vaccines Licensed for Use in the United States listing. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "fda-mresvia",
      "name": "mRESVIA",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "RSV",
      "platform": "See FDA product page / label",
      "currentStage": "approved",
      "jurisdictionStatus": [
        {
          "jurisdiction": "US",
          "status": "approved",
          "date": "2024-05-31",
          "dateType": "regulator_confirmed",
          "notes": "FDA approval / licensure action (public FDA materials)"
        }
      ],
      "linkedTrials": [],
      "expectedMilestone": "US-licensed — see product label / ACIP for use; further supplements may expand indication",
      "sourceType": "FDA CBER regulatory listing (Tier 3)",
      "sourceCitation": {
        "label": "FDA — mRESVIA",
        "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/mresvia",
        "date": "2024-05-31"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "FDA CBER licensed / approved vaccine (regulator-confirmed US listing). First mRNA RSV vaccine approved by FDA (May 2024); subsequent risk-group expansions per label. May also have later supplements (strain updates, age expansions); see product page."
    },
    {
      "candidateId": "ctgov-mcv4-cansino-biologics-inc",
      "name": "MCV4",
      "developer": "CanSino Biologics Inc.",
      "targetDisease": "Epidemic Meningitis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-08-15",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06389513",
        "NCT05935176",
        "NCT06226714",
        "NCT06700148"
      ],
      "trialSubEntries": [
        {
          "trialName": "Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants",
          "nctId": "NCT06389513",
          "phase": "PHASE4",
          "population": "Epidemic Meningitis",
          "comparator": "",
          "expectedReadout": "2025-12",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector",
          "nctId": "NCT05935176",
          "phase": "PHASE4",
          "population": "Epidemic Meningitis",
          "comparator": "",
          "expectedReadout": "2026-05-15",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds",
          "nctId": "NCT06226714",
          "phase": "PHASE3",
          "population": "Meningococcal Meningitis",
          "comparator": "",
          "expectedReadout": "2024-09-26",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds",
          "nctId": "NCT06700148",
          "phase": "PHASE3",
          "population": "Meningococcal Meningitis",
          "comparator": "",
          "expectedReadout": "2025-08-30",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06389513",
        "url": "https://clinicaltrials.gov/study/NCT06389513",
        "date": "2025-08-15"
      },
      "additionalCitations": [
        {
          "label": "NCT05935176 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05935176",
          "date": "2026-07-10"
        },
        {
          "label": "NCT06226714 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06226714",
          "date": "2026-07-10"
        },
        {
          "label": "NCT06700148 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06700148",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "Auto-grouped from 4 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-1273-variant-containing-formulation-modernatx-inc",
      "name": "mRNA-1273 Variant-containing Formulation",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "COVID-19",
      "platform": "mRNA",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-03-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06585241"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations",
          "nctId": "NCT06585241",
          "phase": "PHASE4",
          "population": "SARS-CoV-2",
          "comparator": "",
          "expectedReadout": "2026-12-31",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-12-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06585241",
        "url": "https://clinicaltrials.gov/study/NCT06585241",
        "date": "2026-03-27"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-vaxigrip-tetra-sanofi-pasteur-europe-aarhus-university-hospital",
      "name": "Vaxigrip Tetra Sanofi Pasteur Europe",
      "developer": "Aarhus University Hospital",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-05-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05585983"
      ],
      "trialSubEntries": [
        {
          "trialName": "INfluenza VaccInation To Mitigate typE 1 Diabetes",
          "nctId": "NCT05585983",
          "phase": "PHASE4",
          "population": "Diabetes Mellitus, Type 1",
          "comparator": "",
          "expectedReadout": "2026-05-01",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-05-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05585983",
        "url": "https://clinicaltrials.gov/study/NCT05585983",
        "date": "2025-05-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-recombinant-zoster-vaccine-glaxosmithkline",
      "name": "Recombinant zoster vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Varicella / Zoster",
      "platform": "Protein / subunit",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-12",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07502560"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population A",
          "nctId": "NCT07502560",
          "phase": "PHASE4",
          "population": "Herpes Zoster",
          "comparator": "",
          "expectedReadout": "2030-04-01",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2030-04-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07502560",
        "url": "https://clinicaltrials.gov/study/NCT07502560",
        "date": "2026-05-12"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-sipv-sinovac-biotech-co-ltd",
      "name": "sIPV",
      "developer": "Sinovac Biotech Co., Ltd",
      "targetDisease": "Polio",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-01-21",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07354269"
      ],
      "trialSubEntries": [
        {
          "trialName": "Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations",
          "nctId": "NCT07354269",
          "phase": "PHASE4",
          "population": "Poliomyelitis",
          "comparator": "",
          "expectedReadout": "2026-04-11",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-04-11 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07354269",
        "url": "https://clinicaltrials.gov/study/NCT07354269",
        "date": "2026-01-21"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "polio-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-moderna-covid-19-vaccine-well-konnect-healthcare-services-and-re",
      "name": "Moderna COVID-19 Vaccine",
      "developer": "Well- Konnect Healthcare Services and Research Firm",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2024-11-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06441955"
      ],
      "trialSubEntries": [
        {
          "trialName": "Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.",
          "nctId": "NCT06441955",
          "phase": "PHASE4",
          "population": "COVID-19, Long Haul",
          "comparator": "",
          "expectedReadout": "2030-09-30",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2030-09-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06441955",
        "url": "https://clinicaltrials.gov/study/NCT06441955",
        "date": "2024-11-27"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-2wipv-1sipv-sinovac-biotech-co-ltd",
      "name": "3wIPV",
      "developer": "Sinovac Biotech Co., Ltd",
      "targetDisease": "Polio",
      "platform": "Inactivated",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-03-09",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07457060"
      ],
      "trialSubEntries": [
        {
          "trialName": "Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine",
          "nctId": "NCT07457060",
          "phase": "PHASE4",
          "population": "Poliomyelitis",
          "comparator": "",
          "expectedReadout": "2026-09-08",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-09-08 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07457060",
        "url": "https://clinicaltrials.gov/study/NCT07457060",
        "date": "2026-03-09"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "polio-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-vaicella-vaccine-dtap-on-day-0-mmr-on-day-30-sinovac-dalian-vacc",
      "name": "Varicella Vaccine",
      "developer": "Sinovac (Dalian) Vaccine Technology Co., Ltd.",
      "targetDisease": "Measles / Mumps / Rubella",
      "platform": "Live attenuated",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-03-24",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06891872"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine",
          "nctId": "NCT06891872",
          "phase": "PHASE4",
          "population": "Varicella (chickenpox), MMR Vaccine, DTaP Vaccine",
          "comparator": "",
          "expectedReadout": "2025-12",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06891872",
        "url": "https://clinicaltrials.gov/study/NCT06891872",
        "date": "2025-03-24"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "mmr-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-rsv-vaccination-arexvy-glaxosmithkline-chinese-university-of-hon",
      "name": "RSV vaccination (Arexvy, GlaxoSmithKline)",
      "developer": "Chinese University of Hong Kong",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-04-13",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07508644"
      ],
      "trialSubEntries": [
        {
          "trialName": "RSV Vaccination to Reduce Recurrent AECOPD",
          "nctId": "NCT07508644",
          "phase": "PHASE4",
          "population": "COPD, RSV",
          "comparator": "",
          "expectedReadout": "2030-06-30",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2030-06-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07508644",
        "url": "https://clinicaltrials.gov/study/NCT07508644",
        "date": "2026-04-13"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-prophylactic-quadrivalent-hpv-vaccine-merck-gardasil-partha-basu",
      "name": "Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)",
      "developer": "Partha Basu",
      "targetDisease": "HPV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2023-09-28",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00923702"
      ],
      "trialSubEntries": [
        {
          "trialName": "Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India",
          "nctId": "NCT00923702",
          "phase": "PHASE4",
          "population": "Cervical Cancer, Cervical Precancerous Lesions",
          "comparator": "",
          "expectedReadout": "2017-01",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2017-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00923702",
        "url": "https://clinicaltrials.gov/study/NCT00923702",
        "date": "2023-09-28"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-1273-moderna-covid-19-vaccine-tor-biering-s-rensen",
      "name": "mRNA-1273 (Moderna COVID-19 vaccine)",
      "developer": "Tor Biering-Sørensen",
      "targetDisease": "COVID-19",
      "platform": "mRNA",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-03-16",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07279766"
      ],
      "trialSubEntries": [
        {
          "trialName": "Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Wit",
          "nctId": "NCT07279766",
          "phase": "PHASE4",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2026-08",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-08 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07279766",
        "url": "https://clinicaltrials.gov/study/NCT07279766",
        "date": "2026-03-16"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-healive-hepatitis-a-vacine-human-diploid-cell-inactivated-sinova",
      "name": "Healive (hepatitis A vacine(human diploid cell), inactivated)",
      "developer": "Sinovac Biotech Co., Ltd",
      "targetDisease": "Hepatitis A",
      "platform": "Inactivated",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2024-08-21",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06058416"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old",
          "nctId": "NCT06058416",
          "phase": "PHASE4",
          "population": "Hepatitis A",
          "comparator": "",
          "expectedReadout": "2028-03-17",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-03-17 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06058416",
        "url": "https://clinicaltrials.gov/study/NCT06058416",
        "date": "2024-08-21"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hepatitis-a-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-moderna-rsv-vaccine-emory-university",
      "name": "Moderna RSV vaccine",
      "developer": "Emory University",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-01-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07185399"
      ],
      "trialSubEntries": [
        {
          "trialName": "Systems Biological Analysis of Immune Responses to RSV Vaccine",
          "nctId": "NCT07185399",
          "phase": "PHASE4",
          "population": "Respiratory Syncytial Virus (RSV)",
          "comparator": "",
          "expectedReadout": "2026-07",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-07 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07185399",
        "url": "https://clinicaltrials.gov/study/NCT07185399",
        "date": "2026-01-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-rmenb-omv-nz-glaxosmithkline",
      "name": "rMenB+OMV NZ",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Meningococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-04-06",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06113198"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants ",
          "nctId": "NCT06113198",
          "phase": "PHASE4",
          "population": "Meningitis, Meningococcal",
          "comparator": "",
          "expectedReadout": "2026-09-07",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-09-07 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06113198",
        "url": "https://clinicaltrials.gov/study/NCT06113198",
        "date": "2026-04-06"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-1273-modernatx-inc",
      "name": "mRNA-1273",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "COVID-19",
      "platform": "mRNA",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-04-28",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07266558"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig",
          "nctId": "NCT07266558",
          "phase": "PHASE4",
          "population": "SARS-CoV-2",
          "comparator": "",
          "expectedReadout": "2027-06-16",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-06-16 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07266558",
        "url": "https://clinicaltrials.gov/study/NCT07266558",
        "date": "2026-04-28"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-nvx-cov2705-novavax",
      "name": "NVX-CoV2705",
      "developer": "Novavax",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07086222"
      ],
      "trialSubEntries": [
        {
          "trialName": "Efficacy and Safety of NVX-CoV2705",
          "nctId": "NCT07086222",
          "phase": "PHASE4",
          "population": "COVID-19, Sars-CoV-2 Infection",
          "comparator": "",
          "expectedReadout": "2026-11-18",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-11-18 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07086222",
        "url": "https://clinicaltrials.gov/study/NCT07086222",
        "date": "2026-05-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-live-attenuated-varicella-vaccine-sinovac-dalian-vaccine-technol",
      "name": "Live Attenuated Varicella Vaccine",
      "developer": "Sinovac (Dalian) Vaccine Technology Co., Ltd.",
      "targetDisease": "Varicella / Zoster",
      "platform": "Live attenuated",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-01-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06484686"
      ],
      "trialSubEntries": [
        {
          "trialName": "An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine",
          "nctId": "NCT06484686",
          "phase": "PHASE4",
          "population": "Varicella",
          "comparator": "",
          "expectedReadout": "2028-12",
          "status": "ENROLLING_BY_INVITATION"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06484686",
        "url": "https://clinicaltrials.gov/study/NCT06484686",
        "date": "2025-01-27"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-investigational-live-attenuated-varicella-vaccine-sinovac-dalian",
      "name": "Placebo (Freeze Dired Dilution)",
      "developer": "Sinovac (Dalian) Vaccine Technology Co., Ltd.",
      "targetDisease": "Varicella / Zoster",
      "platform": "Live attenuated",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-01-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05095701"
      ],
      "trialSubEntries": [
        {
          "trialName": "An Immunity Persistence Study of Live Attenuated Varicella Vaccine",
          "nctId": "NCT05095701",
          "phase": "PHASE4",
          "population": "Varicella",
          "comparator": "",
          "expectedReadout": "2021-12-19",
          "status": "ENROLLING_BY_INVITATION"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2021-12-19 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05095701",
        "url": "https://clinicaltrials.gov/study/NCT05095701",
        "date": "2025-01-27"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-cervarix-glaxosmithkline",
      "name": "Havrix",
      "developer": "GlaxoSmithKline",
      "targetDisease": "HPV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2019-11-05",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00730847",
        "NCT02082639"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine",
          "nctId": "NCT00730847",
          "phase": "PHASE4",
          "population": "Human Papillomavirus Infection Leading to Cervical Cancer",
          "comparator": "",
          "expectedReadout": "2012-01-16",
          "status": "TERMINATED"
        },
        {
          "trialName": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-a",
          "nctId": "NCT02082639",
          "phase": "PHASE3",
          "population": "Infections, Papillomavirus",
          "comparator": "",
          "expectedReadout": "2015-08",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2012-01-16 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00730847",
        "url": "https://clinicaltrials.gov/study/NCT00730847",
        "date": "2019-11-05"
      },
      "additionalCitations": [
        {
          "label": "NCT02082639 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT02082639",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED, WITHDRAWN",
      "stageAtDiscontinuation": "approved"
    },
    {
      "candidateId": "ctgov-azd1222-astrazeneca",
      "name": "AZD1222",
      "developer": "AstraZeneca",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-01-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05057897",
        "NCT04540393"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults",
          "nctId": "NCT05057897",
          "phase": "PHASE4",
          "population": "COVID-19, SARS-CoV-2",
          "comparator": "",
          "expectedReadout": "2023-04-19",
          "status": "TERMINATED"
        },
        {
          "trialName": "AZD1222 Vaccine for the Prevention of COVID-19",
          "nctId": "NCT04540393",
          "phase": "PHASE3",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2020-12-04",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-04-19 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05057897",
        "url": "https://clinicaltrials.gov/study/NCT05057897",
        "date": "2025-01-27"
      },
      "additionalCitations": [
        {
          "label": "NCT04540393 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT04540393",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED, WITHDRAWN",
      "stageAtDiscontinuation": "approved"
    },
    {
      "candidateId": "ctgov-mrna-covid-19-vaccine-novartis-pharmaceuticals",
      "name": "mRNA COVID-19 vaccine",
      "developer": "Novartis Pharmaceuticals",
      "targetDisease": "COVID-19",
      "platform": "mRNA",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-05-16",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04878211"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab",
          "nctId": "NCT04878211",
          "phase": "PHASE4",
          "population": "Relapsing Multiple Sclerosis (RMS)",
          "comparator": "",
          "expectedReadout": "2023-04-14",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-04-14 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04878211",
        "url": "https://clinicaltrials.gov/study/NCT04878211",
        "date": "2025-05-16"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "approved"
    },
    {
      "candidateId": "ctgov-dtp-hb-hib-vaccine-serum-institute-of-india-pvt-ltd",
      "name": "DTP-HB-Hib vaccine",
      "developer": "Serum Institute of India Pvt. Ltd.",
      "targetDisease": "Hib",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2018-09-11",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02409095"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study Comparing DTP-HB-Hib by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Infants",
          "nctId": "NCT02409095",
          "phase": "PHASE4",
          "population": "Immune Response to DTP-HB-Hib Vaccine",
          "comparator": "",
          "expectedReadout": "2016-02",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2016-02 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02409095",
        "url": "https://clinicaltrials.gov/study/NCT02409095",
        "date": "2018-09-11"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hib-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "approved"
    },
    {
      "candidateId": "ctgov-pneumo-23-wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer",
      "name": "Pneumo 23",
      "developer": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "targetDisease": "Pneumococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2006-08-24",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00368186"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.",
          "nctId": "NCT00368186",
          "phase": "PHASE4",
          "population": "Pneumococcal Infections",
          "comparator": "",
          "expectedReadout": "TBD",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "See linked ClinicalTrials.gov records for primary completion dates",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00368186",
        "url": "https://clinicaltrials.gov/study/NCT00368186",
        "date": "2006-08-24"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "approved"
    },
    {
      "candidateId": "ctgov-rabipur-glaxosmithkline",
      "name": "Rabipur",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Rabies",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2018-02-26",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03192371"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-e",
          "nctId": "NCT03192371",
          "phase": "PHASE4",
          "population": "Virus Diseases",
          "comparator": "",
          "expectedReadout": "2019-05-12",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2019-05-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03192371",
        "url": "https://clinicaltrials.gov/study/NCT03192371",
        "date": "2018-02-26"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rabies-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "approved"
    },
    {
      "candidateId": "ctgov-havrix-glaxosmithkline",
      "name": "Havrix®",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Hepatitis A",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2018-03-02",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03183492"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Inf",
          "nctId": "NCT03183492",
          "phase": "PHASE4",
          "population": "Hepatitis A",
          "comparator": "",
          "expectedReadout": "2019-01-28",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2019-01-28 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03183492",
        "url": "https://clinicaltrials.gov/study/NCT03183492",
        "date": "2018-03-02"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hepatitis-a-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "approved"
    },
    {
      "candidateId": "ctgov-experimental-vaccine-1-sinovac-research-and-development-co-ltd",
      "name": "Experimental vaccine 1",
      "developer": "Sinovac Research and Development Co., Ltd.",
      "targetDisease": "COVID-19",
      "platform": "Inactivated",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2022-08-11",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05165732"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manu",
          "nctId": "NCT05165732",
          "phase": "PHASE4",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2023-03-20",
          "status": "SUSPENDED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-03-20 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05165732",
        "url": "https://clinicaltrials.gov/study/NCT05165732",
        "date": "2022-08-11"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: SUSPENDED",
      "stageAtDiscontinuation": "approved"
    },
    {
      "candidateId": "ctgov-bcg-denmark-1331-statens-serum-institute-bandim-health-project",
      "name": "BCG-Denmark 1331 (Statens Serum Institute)",
      "developer": "Bandim Health Project",
      "targetDisease": "Tuberculosis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2026-05-26",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02504203"
      ],
      "trialSubEntries": [
        {
          "trialName": "Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial",
          "nctId": "NCT02504203",
          "phase": "PHASE4",
          "population": "Infant Mortality, BCG",
          "comparator": "",
          "expectedReadout": "2021-06",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2021-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02504203",
        "url": "https://clinicaltrials.gov/study/NCT02504203",
        "date": "2026-05-26"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "approved"
    },
    {
      "candidateId": "ctgov-9vhpv-vaccine-merck-sharp-dohme-llc",
      "name": "9vHPV vaccine",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Papillomavirus Infections",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2022-09-02",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05450705",
        "NCT05314023",
        "NCT05285826",
        "NCT04199689",
        "NCT04708041"
      ],
      "trialSubEntries": [
        {
          "trialName": "V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)",
          "nctId": "NCT05450705",
          "phase": "PHASE3",
          "population": "Papillomavirus Infections",
          "comparator": "",
          "expectedReadout": "2029-08-03",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)",
          "nctId": "NCT05314023",
          "phase": "PHASE3",
          "population": "Genital Warts",
          "comparator": "",
          "expectedReadout": "2029-02-19",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)",
          "nctId": "NCT05285826",
          "phase": "PHASE3",
          "population": "Papillomavirus Infections",
          "comparator": "",
          "expectedReadout": "2029-05-25",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHP",
          "nctId": "NCT04199689",
          "phase": "PHASE3",
          "population": "Papillomavirus Infections",
          "comparator": "",
          "expectedReadout": "2027-08-27",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)",
          "nctId": "NCT04708041",
          "phase": "PHASE3",
          "population": "Papillomavirus Infections",
          "comparator": "",
          "expectedReadout": "2029-10-23",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2029-08-03 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05450705",
        "url": "https://clinicaltrials.gov/study/NCT05450705",
        "date": "2022-09-02"
      },
      "additionalCitations": [
        {
          "label": "NCT05314023 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05314023",
          "date": "2026-07-10"
        },
        {
          "label": "NCT05285826 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05285826",
          "date": "2026-07-10"
        },
        {
          "label": "NCT04199689 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT04199689",
          "date": "2026-07-10"
        },
        {
          "label": "NCT04708041 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT04708041",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 5 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pcv21-vaccine-sanofi",
      "name": "Rotarix",
      "developer": "Sanofi",
      "targetDisease": "Pneumococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-02-13",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06824181",
        "NCT06975878",
        "NCT06824194",
        "NCT07348692"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjug",
          "nctId": "NCT06824181",
          "phase": "PHASE3",
          "population": "Pneumococcal Immunization",
          "comparator": "",
          "expectedReadout": "2027-09-10",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",
          "nctId": "NCT06975878",
          "phase": "PHASE3",
          "population": "Pneumococcal Immunization, Healthy Volunteers",
          "comparator": "",
          "expectedReadout": "2027-08-25",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",
          "nctId": "NCT06824194",
          "phase": "PHASE3",
          "population": "Pneumococcal Immunization",
          "comparator": "",
          "expectedReadout": "2027-10-22",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age",
          "nctId": "NCT07348692",
          "phase": "PHASE3",
          "population": "Pneumococcal Immunization, Healthy Volunteers",
          "comparator": "",
          "expectedReadout": "2027-06-07",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-09-10 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06824181",
        "url": "https://clinicaltrials.gov/study/NCT06824181",
        "date": "2026-02-13"
      },
      "additionalCitations": [
        {
          "label": "NCT06975878 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06975878",
          "date": "2026-07-10"
        },
        {
          "label": "NCT06824194 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06824194",
          "date": "2026-07-10"
        },
        {
          "label": "NCT07348692 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07348692",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 4 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-rsvpref-pfizer",
      "name": "RSVpreF",
      "developer": "Pfizer",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-01-28",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05035212",
        "NCT07543380",
        "NCT06866405",
        "NCT07653100"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.",
          "nctId": "NCT05035212",
          "phase": "PHASE3",
          "population": "Lower Respiratory Tract Illness",
          "comparator": "",
          "expectedReadout": "2027-01-18",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.",
          "nctId": "NCT07543380",
          "phase": "PHASE3",
          "population": "Respiratory Syncytial Virus (RSV)",
          "comparator": "",
          "expectedReadout": "2026-08-31",
          "status": "RECRUITING"
        },
        {
          "trialName": "A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Sin",
          "nctId": "NCT06866405",
          "phase": "PHASE3",
          "population": "RSV Infection",
          "comparator": "",
          "expectedReadout": "2028-02-24",
          "status": "RECRUITING"
        },
        {
          "trialName": "A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF",
          "nctId": "NCT07653100",
          "phase": "PHASE3",
          "population": "Respiratory Syncytial Virus (RSV)",
          "comparator": "",
          "expectedReadout": "2027-01-25",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-01-18 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05035212",
        "url": "https://clinicaltrials.gov/study/NCT05035212",
        "date": "2026-01-28"
      },
      "additionalCitations": [
        {
          "label": "NCT07543380 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07543380",
          "date": "2026-07-10"
        },
        {
          "label": "NCT06866405 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06866405",
          "date": "2026-07-10"
        },
        {
          "label": "NCT07653100 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07653100",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 4 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pg4-pfizer",
      "name": "PG4",
      "developer": "Pfizer",
      "targetDisease": "Pneumococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-07-09",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07660198",
        "NCT07573462",
        "NCT07629440",
        "NCT06524414"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adoles",
          "nctId": "NCT07660198",
          "phase": "PHASE3",
          "population": "Pneumococcal Disease",
          "comparator": "",
          "expectedReadout": "2027-12-02",
          "status": "RECRUITING"
        },
        {
          "trialName": "A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants",
          "nctId": "NCT07573462",
          "phase": "PHASE3",
          "population": "Pneumococcal Disease",
          "comparator": "",
          "expectedReadout": "2028-12-30",
          "status": "RECRUITING"
        },
        {
          "trialName": "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.",
          "nctId": "NCT07629440",
          "phase": "PHASE3",
          "population": "Pneumococcal Disease",
          "comparator": "",
          "expectedReadout": "2029-06-05",
          "status": "RECRUITING"
        },
        {
          "trialName": "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants",
          "nctId": "NCT06524414",
          "phase": "PHASE2",
          "population": "Pneumococcal Disease",
          "comparator": "",
          "expectedReadout": "2027-05-01",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-12-02 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07660198",
        "url": "https://clinicaltrials.gov/study/NCT07660198",
        "date": "2026-07-09"
      },
      "additionalCitations": [
        {
          "label": "NCT07573462 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07573462",
          "date": "2026-07-10"
        },
        {
          "label": "NCT07629440 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07629440",
          "date": "2026-07-10"
        },
        {
          "label": "NCT06524414 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06524414",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 4 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-experimental-vaccine-sinovac-biotech-co-ltd",
      "name": "experimental vaccine",
      "developer": "Sinovac Biotech Co., Ltd",
      "targetDisease": "Meningococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-04-01",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07505888",
        "NCT07505836",
        "NCT07505823",
        "NCT07505810"
      ],
      "trialSubEntries": [
        {
          "trialName": "Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years",
          "nctId": "NCT07505888",
          "phase": "PHASE3",
          "population": "Epidemic Meningitis, Meningococcal Vaccines",
          "comparator": "",
          "expectedReadout": "2026-11",
          "status": "NOT_YET_RECRUITING"
        },
        {
          "trialName": "Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months",
          "nctId": "NCT07505836",
          "phase": "PHASE3",
          "population": "Epidemic Meningitis, Meningococcal Vaccines",
          "comparator": "",
          "expectedReadout": "2027-01",
          "status": "NOT_YET_RECRUITING"
        },
        {
          "trialName": "Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months",
          "nctId": "NCT07505823",
          "phase": "PHASE3",
          "population": "Epidemic Meningitis, Meningococcal Vaccines",
          "comparator": "",
          "expectedReadout": "2027-04",
          "status": "NOT_YET_RECRUITING"
        },
        {
          "trialName": "Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months",
          "nctId": "NCT07505810",
          "phase": "PHASE3",
          "population": "Epidemic Meningitis, Meningococcal Vaccines",
          "comparator": "",
          "expectedReadout": "2027-04",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-11 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07505888",
        "url": "https://clinicaltrials.gov/study/NCT07505888",
        "date": "2026-04-01"
      },
      "additionalCitations": [
        {
          "label": "NCT07505836 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07505836",
          "date": "2026-07-10"
        },
        {
          "label": "NCT07505823 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07505823",
          "date": "2026-07-10"
        },
        {
          "label": "NCT07505810 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07505810",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "Auto-grouped from 4 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-diphtheria-tetanus-and-acellular-pertussis-three-components-comb",
      "name": "Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP",
      "developer": "CanSino Biologics Inc.",
      "targetDisease": "Diphtheria / Tetanus / Pertussis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-03-17",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05951725",
        "NCT06857370",
        "NCT05091619"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)",
          "nctId": "NCT05951725",
          "phase": "PHASE3",
          "population": "Diphtheria, Tetanus and Acellular Pertussis",
          "comparator": "",
          "expectedReadout": "2025-04-01",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine",
          "nctId": "NCT06857370",
          "phase": "PHASE3",
          "population": "Diphtheria, Tetanus and Acellular Pertussis",
          "comparator": "",
          "expectedReadout": "2026-01",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed",
          "nctId": "NCT05091619",
          "phase": "PHASE3",
          "population": "Whooping Cough, Diphtheria, Tetanus",
          "comparator": "",
          "expectedReadout": "2024-01-22",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-04-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05951725",
        "url": "https://clinicaltrials.gov/study/NCT05951725",
        "date": "2025-03-17"
      },
      "additionalCitations": [
        {
          "label": "NCT06857370 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06857370",
          "date": "2026-07-10"
        },
        {
          "label": "NCT05091619 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05091619",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "dtap-vaccine.html",
      "note": "Auto-grouped from 3 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-31-valent-pneumococcal-conjugate-vaccine-vaxcyte-inc",
      "name": "PCV20",
      "developer": "Vaxcyte, Inc.",
      "targetDisease": "Pneumococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-15",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07284654",
        "NCT07365826",
        "NCT07425392"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49",
          "nctId": "NCT07284654",
          "phase": "PHASE3",
          "population": "Pneumococcal Vaccines",
          "comparator": "",
          "expectedReadout": "2027-01",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 5",
          "nctId": "NCT07365826",
          "phase": "PHASE3",
          "population": "Pneumococcal Vaccines",
          "comparator": "",
          "expectedReadout": "2027-03",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination",
          "nctId": "NCT07425392",
          "phase": "PHASE3",
          "population": "Pneumococcal Vaccines",
          "comparator": "",
          "expectedReadout": "2027-03",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07284654",
        "url": "https://clinicaltrials.gov/study/NCT07284654",
        "date": "2026-05-15"
      },
      "additionalCitations": [
        {
          "label": "NCT07365826 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07365826",
          "date": "2026-07-10"
        },
        {
          "label": "NCT07425392 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07425392",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 3 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-vla1553-valneva-austria-gmbh",
      "name": "VLA1553",
      "developer": "Valneva Austria GmbH",
      "targetDisease": "Chikungunya",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2024-12-02",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06028841",
        "NCT07133178",
        "NCT04838444"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)",
          "nctId": "NCT06028841",
          "phase": "PHASE3",
          "population": "Chikungunya Virus Infection",
          "comparator": "",
          "expectedReadout": "2024-08-27",
          "status": "WITHDRAWN"
        },
        {
          "trialName": "A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children",
          "nctId": "NCT07133178",
          "phase": "PHASE3",
          "population": "Chikungunya Virus Infection",
          "comparator": "",
          "expectedReadout": "2026-12",
          "status": "WITHDRAWN"
        },
        {
          "trialName": "Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)",
          "nctId": "NCT04838444",
          "phase": "PHASE3",
          "population": "Chikungunya Virus Infection",
          "comparator": "",
          "expectedReadout": "2023-03-03",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2024-08-27 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06028841",
        "url": "https://clinicaltrials.gov/study/NCT06028841",
        "date": "2024-12-02"
      },
      "additionalCitations": [
        {
          "label": "NCT07133178 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07133178",
          "date": "2026-07-10"
        },
        {
          "label": "NCT04838444 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT04838444",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 3 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-1647-modernatx-inc",
      "name": "mRNA-1647",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "CMV",
      "platform": "mRNA",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-12-15",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05085366",
        "NCT06133010",
        "NCT05683457"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Parti",
          "nctId": "NCT05085366",
          "phase": "PHASE3",
          "population": "Cytomegalovirus Infection",
          "comparator": "",
          "expectedReadout": "2025-11-04",
          "status": "TERMINATED"
        },
        {
          "trialName": "A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients",
          "nctId": "NCT06133010",
          "phase": "PHASE2",
          "population": "Cytomegalovirus Infection",
          "comparator": "",
          "expectedReadout": "2027-02-14",
          "status": "WITHDRAWN"
        },
        {
          "trialName": "A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hem",
          "nctId": "NCT05683457",
          "phase": "PHASE2",
          "population": "Cytomegalovirus Infection",
          "comparator": "",
          "expectedReadout": "2026-08-01",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-11-04 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05085366",
        "url": "https://clinicaltrials.gov/study/NCT05085366",
        "date": "2025-12-15"
      },
      "additionalCitations": [
        {
          "label": "NCT06133010 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06133010",
          "date": "2026-07-10"
        },
        {
          "label": "NCT05683457 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05683457",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 3 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-rsvpref3-oa-vaccine-glaxosmithkline",
      "name": "Placebo",
      "developer": "GlaxoSmithKline",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07220109",
        "NCT06534892"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 5",
          "nctId": "NCT07220109",
          "phase": "PHASE3",
          "population": "Respiratory Syncytial Virus Infections",
          "comparator": "",
          "expectedReadout": "2026-09-25",
          "status": "RECRUITING"
        },
        {
          "trialName": "An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytia",
          "nctId": "NCT06534892",
          "phase": "PHASE3",
          "population": "Respiratory Syncytial Virus Infections",
          "comparator": "",
          "expectedReadout": "2026-09-30",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-09-25 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07220109",
        "url": "https://clinicaltrials.gov/study/NCT07220109",
        "date": "2026-05-27"
      },
      "additionalCitations": [
        {
          "label": "NCT06534892 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06534892",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-investigational-varicella-vaccine-glaxosmithkline",
      "name": "Marketed varicella vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Varicella / Zoster",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06693895",
        "NCT06806137"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age",
          "nctId": "NCT06693895",
          "phase": "PHASE3",
          "population": "Chickenpox",
          "comparator": "",
          "expectedReadout": "2026-11-23",
          "status": "RECRUITING"
        },
        {
          "trialName": "A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Heal",
          "nctId": "NCT06806137",
          "phase": "PHASE3",
          "population": "Chickenpox",
          "comparator": "",
          "expectedReadout": "2026-12-14",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-11-23 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06693895",
        "url": "https://clinicaltrials.gov/study/NCT06693895",
        "date": "2026-05-29"
      },
      "additionalCitations": [
        {
          "label": "NCT06806137 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06806137",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-sinovac-pcv13-sinovac-life-sciences-co-ltd",
      "name": "Prevnar®",
      "developer": "Sinovac Life Sciences Co., Ltd.",
      "targetDisease": "Pneumococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-01-28",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06617715",
        "NCT07593924"
      ],
      "trialSubEntries": [
        {
          "trialName": "Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine",
          "nctId": "NCT06617715",
          "phase": "PHASE3",
          "population": "Pneumococcal Infectious Disease",
          "comparator": "",
          "expectedReadout": "2026-05-12",
          "status": "RECRUITING"
        },
        {
          "trialName": "Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)",
          "nctId": "NCT07593924",
          "phase": "PHASE3",
          "population": "Pneumococcal Infectious Diseases",
          "comparator": "",
          "expectedReadout": "2027-07",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-05-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06617715",
        "url": "https://clinicaltrials.gov/study/NCT06617715",
        "date": "2026-01-28"
      },
      "additionalCitations": [
        {
          "label": "NCT07593924 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07593924",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-rabies-vaccine-serum-free-vero-cell-freeze-dried-sinovac-biotech",
      "name": "Verorab®",
      "developer": "Sinovac Biotech Co., Ltd",
      "targetDisease": "Rabies",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-07-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07055295",
        "NCT07055880"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen",
          "nctId": "NCT07055295",
          "phase": "PHASE3",
          "population": "Rabies",
          "comparator": "",
          "expectedReadout": "2026-12-30",
          "status": "NOT_YET_RECRUITING"
        },
        {
          "trialName": "Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)",
          "nctId": "NCT07055880",
          "phase": "PHASE2",
          "population": "Rabies",
          "comparator": "",
          "expectedReadout": "2026-01-15",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-12-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07055295",
        "url": "https://clinicaltrials.gov/study/NCT07055295",
        "date": "2025-07-08"
      },
      "additionalCitations": [
        {
          "label": "NCT07055880 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07055880",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rabies-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-tetanus-reduced-diphtheria-and-acellular-pertussis-five-componen",
      "name": "23-valent Pneumococcal Polysaccharide Vaccine (PPV23)",
      "developer": "CanSino Biologics Inc.",
      "targetDisease": "Diphtheria / Tetanus / Pertussis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-03-17",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06708286",
        "NCT06056050"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)",
          "nctId": "NCT06708286",
          "phase": "PHASE2,PHASE3",
          "population": "Diphtheria, Tetanus, Pertussis",
          "comparator": "",
          "expectedReadout": "2025-05-30",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)",
          "nctId": "NCT06056050",
          "phase": "PHASE1",
          "population": "Diphtheria, Tetanus, Pertussis",
          "comparator": "",
          "expectedReadout": "2024-04-13",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-05-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06708286",
        "url": "https://clinicaltrials.gov/study/NCT06708286",
        "date": "2025-03-17"
      },
      "additionalCitations": [
        {
          "label": "NCT06056050 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06056050",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "dtap-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-1345-modernatx-inc",
      "name": "mRNA-1345",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "RSV",
      "platform": "mRNA",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-08-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06067230",
        "NCT05743881"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in",
          "nctId": "NCT06067230",
          "phase": "PHASE3",
          "population": "Respiratory Syncytial Virus",
          "comparator": "",
          "expectedReadout": "2026-07-30",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months",
          "nctId": "NCT05743881",
          "phase": "PHASE1",
          "population": "Respiratory Syncytial Virus, Human Metapneumovirus",
          "comparator": "",
          "expectedReadout": "2029-08-31",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-07-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06067230",
        "url": "https://clinicaltrials.gov/study/NCT06067230",
        "date": "2025-08-08"
      },
      "additionalCitations": [
        {
          "label": "NCT05743881 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05743881",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-bivalent-bnt162b2-original-omicron-ba-4-ba-5-3-microgram-dose-bi",
      "name": "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose",
      "developer": "BioNTech SE",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-04-13",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05543616",
        "NCT05630352"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children",
          "nctId": "NCT05543616",
          "phase": "PHASE3",
          "population": "SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19",
          "comparator": "",
          "expectedReadout": "2026-07-23",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children",
          "nctId": "NCT05630352",
          "phase": "PHASE1",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2026-07-13",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-07-23 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05543616",
        "url": "https://clinicaltrials.gov/study/NCT05543616",
        "date": "2026-04-13"
      },
      "additionalCitations": [
        {
          "label": "NCT05630352 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05630352",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-tdv-takeda",
      "name": "TDV",
      "developer": "Takeda",
      "targetDisease": "Dengue",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-04-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06579755",
        "NCT06665035"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)",
          "nctId": "NCT06579755",
          "phase": "PHASE3",
          "population": "Dengue Fever",
          "comparator": "",
          "expectedReadout": "2027-04-14",
          "status": "RECRUITING"
        },
        {
          "trialName": "A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers",
          "nctId": "NCT06665035",
          "phase": "PHASE3",
          "population": "Dengue Fever",
          "comparator": "",
          "expectedReadout": "2030-03-03",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-04-14 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06579755",
        "url": "https://clinicaltrials.gov/study/NCT06579755",
        "date": "2026-04-29"
      },
      "additionalCitations": [
        {
          "label": "NCT06665035 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06665035",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-1403-modernatx-inc",
      "name": "mRNA-1403",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "Norovirus",
      "platform": "mRNA",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-13",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06592794",
        "NCT05992935"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute",
          "nctId": "NCT06592794",
          "phase": "PHASE3",
          "population": "Acute Gastroenteritis, Norovirus Acute Gastroenteritis",
          "comparator": "",
          "expectedReadout": "2027-02-15",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute G",
          "nctId": "NCT05992935",
          "phase": "PHASE1,PHASE2",
          "population": "Norovirus Acute Gastroenteritis",
          "comparator": "",
          "expectedReadout": "2026-09-22",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-02-15 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06592794",
        "url": "https://clinicaltrials.gov/study/NCT06592794",
        "date": "2026-05-13"
      },
      "additionalCitations": [
        {
          "label": "NCT05992935 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05992935",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-investigational-varicella-vaccine-lot-1-glaxosmithkline",
      "name": "Marketed varicella vaccine_Lot 1",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Varicella / Zoster",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06740630"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to ",
          "nctId": "NCT06740630",
          "phase": "PHASE3",
          "population": "Chickenpox",
          "comparator": "",
          "expectedReadout": "2026-12-25",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-12-25 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06740630",
        "url": "https://clinicaltrials.gov/study/NCT06740630",
        "date": "2026-05-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mmrvns-glaxosmithkline",
      "name": "MMRV",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Measles / Mumps / Rubella",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-07-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07406360"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, ",
          "nctId": "NCT07406360",
          "phase": "PHASE3",
          "population": "Measles, Measles-Mumps-Rubella+Chickenpox Vaccine",
          "comparator": "",
          "expectedReadout": "2028-02-28",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-02-28 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07406360",
        "url": "https://clinicaltrials.gov/study/NCT07406360",
        "date": "2026-07-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "mmr-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-h5n1-vaccine-arepanrix-gsk-university-health-network-toronto",
      "name": "H5N1 vaccine (Arepanrix, GSK)",
      "developer": "University Health Network, Toronto",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-12-18",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07240558"
      ],
      "trialSubEntries": [
        {
          "trialName": "Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)",
          "nctId": "NCT07240558",
          "phase": "PHASE3",
          "population": "Influenza (Pandemic), Avian Influenza, Vaccination",
          "comparator": "",
          "expectedReadout": "2026-06-30",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-06-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07240558",
        "url": "https://clinicaltrials.gov/study/NCT07240558",
        "date": "2025-12-18"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-yellow-fever-vaccine-live-sanofi",
      "name": "Yellow fever vaccine (live)",
      "developer": "Sanofi",
      "targetDisease": "Yellow fever",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-06",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07103148"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population",
          "nctId": "NCT07103148",
          "phase": "PHASE3",
          "population": "Yellow Fever Immunization",
          "comparator": "",
          "expectedReadout": "2026-08-08",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-08-08 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07103148",
        "url": "https://clinicaltrials.gov/study/NCT07103148",
        "date": "2026-05-06"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "yellow-fever-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-1018-h5-modernatx-inc",
      "name": "mRNA-1018-H5",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "Influenza",
      "platform": "mRNA",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-04-03",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07496450"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults",
          "nctId": "NCT07496450",
          "phase": "PHASE3",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "2027-01-28",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-01-28 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07496450",
        "url": "https://clinicaltrials.gov/study/NCT07496450",
        "date": "2026-04-03"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pcv13i-cansino-biologics-inc",
      "name": "PCV13i",
      "developer": "CanSino Biologics Inc.",
      "targetDisease": "Pneumococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-02-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07017777"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant",
          "nctId": "NCT07017777",
          "phase": "PHASE3",
          "population": "Pneumococcal Infections, Streptococcal Infections, Bacterial Infections",
          "comparator": "",
          "expectedReadout": "2027-02-15",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-02-15 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07017777",
        "url": "https://clinicaltrials.gov/study/NCT07017777",
        "date": "2026-02-27"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-participants-will-receive-one-dose-of-vaccine-0-5-ml-of-sinovac-",
      "name": "Vaxigrip QIV",
      "developer": "Sinovac Biotech Co., Ltd",
      "targetDisease": "Influenza",
      "platform": "Inactivated",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-01-28",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07211152"
      ],
      "trialSubEntries": [
        {
          "trialName": "Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women",
          "nctId": "NCT07211152",
          "phase": "PHASE3",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "2026-03",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-03 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07211152",
        "url": "https://clinicaltrials.gov/study/NCT07211152",
        "date": "2026-01-28"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pcv21-sanofi",
      "name": "PCV21",
      "developer": "Sanofi",
      "targetDisease": "Pneumococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-04-15",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07247188"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Diseas",
          "nctId": "NCT07247188",
          "phase": "PHASE3",
          "population": "Sickle Cell Disease",
          "comparator": "",
          "expectedReadout": "2027-01-07",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-01-07 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07247188",
        "url": "https://clinicaltrials.gov/study/NCT07247188",
        "date": "2026-04-15"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-provarix-sinovac-dalian-vaccine-technology-co-ltd",
      "name": "PROVARIX",
      "developer": "Sinovac (Dalian) Vaccine Technology Co., Ltd.",
      "targetDisease": "Varicella / Zoster",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-03-16",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07475000"
      ],
      "trialSubEntries": [
        {
          "trialName": "Second Dose of Varicella Vaccine in Healthy Children",
          "nctId": "NCT07475000",
          "phase": "PHASE3",
          "population": "Varicella (Chickenpox), Varicella Immunisation",
          "comparator": "",
          "expectedReadout": "2026-07-15",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-07-15 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07475000",
        "url": "https://clinicaltrials.gov/study/NCT07475000",
        "date": "2026-03-16"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-bnt113-biontech-se",
      "name": "BNT113",
      "developer": "BioNTech SE",
      "targetDisease": "HPV",
      "platform": "Protein / subunit",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04534205"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembroliz",
          "nctId": "NCT04534205",
          "phase": "PHASE2,PHASE3",
          "population": "Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer",
          "comparator": "",
          "expectedReadout": "2029-04",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2029-04 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04534205",
        "url": "https://clinicaltrials.gov/study/NCT04534205",
        "date": "2026-05-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-dtpa-glaxosmithkline",
      "name": "dTpa",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Diphtheria / Tetanus / Pertussis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-07-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07596199"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTp",
          "nctId": "NCT07596199",
          "phase": "PHASE3",
          "population": "Diphtheria-Tetanus-acellular Pertussis Vaccines",
          "comparator": "",
          "expectedReadout": "2026-12-11",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-12-11 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07596199",
        "url": "https://clinicaltrials.gov/study/NCT07596199",
        "date": "2026-07-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "dtap-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-dtpa-vaccine-glaxosmithkline",
      "name": "dTpa vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Diphtheria / Tetanus / Pertussis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-07-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07596173"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTp",
          "nctId": "NCT07596173",
          "phase": "PHASE3",
          "population": "Diphtheria-Tetanus-acellular Pertussis Vaccines",
          "comparator": "",
          "expectedReadout": "2026-10-14",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-10-14 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07596173",
        "url": "https://clinicaltrials.gov/study/NCT07596173",
        "date": "2026-07-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "dtap-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-sinovac-rabies-vaccine-sinovac-biotech-co-ltd",
      "name": "Sinovac rabies vaccine",
      "developer": "Sinovac Biotech Co., Ltd",
      "targetDisease": "Rabies",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-02-17",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07416110"
      ],
      "trialSubEntries": [
        {
          "trialName": "Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine",
          "nctId": "NCT07416110",
          "phase": "PHASE3",
          "population": "Rabies (Healthy Volunteers)",
          "comparator": "",
          "expectedReadout": "2026-09-30",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-09-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07416110",
        "url": "https://clinicaltrials.gov/study/NCT07416110",
        "date": "2026-02-17"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rabies-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-walvax-pcv13-tt-walvax-biotechnology-co-ltd",
      "name": "Pfizer PCV13",
      "developer": "Walvax Biotechnology Co., Ltd.",
      "targetDisease": "Pneumococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2024-07-03",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05934890"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13",
          "nctId": "NCT05934890",
          "phase": "PHASE3",
          "population": "Pneumococcal Disease, Invasive",
          "comparator": "",
          "expectedReadout": "2025-03",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-03 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05934890",
        "url": "https://clinicaltrials.gov/study/NCT05934890",
        "date": "2024-07-03"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-batch-1-of-group-acyw135-meningococcal-conjugate-vaccine-crm197-",
      "name": "batch 2 of MCV4",
      "developer": "CanSino Biologics Inc.",
      "targetDisease": "Meningococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-04-03",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06131554"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in ",
          "nctId": "NCT06131554",
          "phase": "PHASE3",
          "population": "Meningococcal Meningitis",
          "comparator": "",
          "expectedReadout": "2024-07-12",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2024-07-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06131554",
        "url": "https://clinicaltrials.gov/study/NCT06131554",
        "date": "2025-04-03"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-rotavac-5d-bharat-biotech-international-limited",
      "name": "ROTAVAC 5D",
      "developer": "Bharat Biotech International Limited",
      "targetDisease": "Rotavirus",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-05-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06200844"
      ],
      "trialSubEntries": [
        {
          "trialName": "The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants",
          "nctId": "NCT06200844",
          "phase": "PHASE3",
          "population": "Rotavirus Infection of Children",
          "comparator": "",
          "expectedReadout": "2025-01-04",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-01-04 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06200844",
        "url": "https://clinicaltrials.gov/study/NCT06200844",
        "date": "2025-05-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rotavirus-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-2-doses-of-vaccine-quadrivalent-recombinant-human-papillomavirus",
      "name": "2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)",
      "developer": "National Vaccine and Serum Institute, China",
      "targetDisease": "HPV",
      "platform": "Protein / subunit",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-01-23",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06632912"
      ],
      "trialSubEntries": [
        {
          "trialName": "Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immuniz",
          "nctId": "NCT06632912",
          "phase": "PHASE3",
          "population": "Human Papillomavirus (HPV) Infection, HPV (Human Papillomavirus)-Associated Carcinoma",
          "comparator": "",
          "expectedReadout": "2032-07",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2032-07 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06632912",
        "url": "https://clinicaltrials.gov/study/NCT06632912",
        "date": "2026-01-23"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-rsvpref3-oa-investigational-vaccine-glaxosmithkline",
      "name": "RSVPreF3 OA investigational vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-03-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04732871"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine i",
          "nctId": "NCT04732871",
          "phase": "PHASE3",
          "population": "Respiratory Syncytial Virus Infections",
          "comparator": "",
          "expectedReadout": "2022-06-06",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2022-06-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04732871",
        "url": "https://clinicaltrials.gov/study/NCT04732871",
        "date": "2026-03-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-cervavac-as-three-dose-regimen-serum-institute-of-india-pvt-ltd",
      "name": "Cervavac as two dose regimen",
      "developer": "Serum Institute of India Pvt. Ltd.",
      "targetDisease": "HPV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-06-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06281119"
      ],
      "trialSubEntries": [
        {
          "trialName": "Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years",
          "nctId": "NCT06281119",
          "phase": "PHASE3",
          "population": "Human Papillomavirus Infection",
          "comparator": "",
          "expectedReadout": "2026-12-31",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-12-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06281119",
        "url": "https://clinicaltrials.gov/study/NCT06281119",
        "date": "2026-06-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pfizer-bivalent-covid-19-vaccine-monash-university",
      "name": "Moderna Bivalent mRNA vaccine",
      "developer": "Monash University",
      "targetDisease": "COVID-19",
      "platform": "mRNA",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-10-03",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05556720"
      ],
      "trialSubEntries": [
        {
          "trialName": "Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Contro",
          "nctId": "NCT05556720",
          "phase": "PHASE3",
          "population": "HIV, Organ Transplantation, Lymphoma, Non-Hodgkin",
          "comparator": "",
          "expectedReadout": "2026-06-30",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-06-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05556720",
        "url": "https://clinicaltrials.gov/study/NCT05556720",
        "date": "2025-10-03"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-bivalent-moderna-murdoch-childrens-research-institute",
      "name": "Novavax",
      "developer": "Murdoch Childrens Research Institute",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-01-02",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05658523"
      ],
      "trialSubEntries": [
        {
          "trialName": "COVID-19 Booster Study in Healthy Adults in Australia",
          "nctId": "NCT05658523",
          "phase": "PHASE3",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2024-10-13",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2024-10-13 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05658523",
        "url": "https://clinicaltrials.gov/study/NCT05658523",
        "date": "2026-01-02"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-menacyw-conjugate-vaccine-sanofi",
      "name": "MenAC conjugate vaccine",
      "developer": "Sanofi",
      "targetDisease": "Meningococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-12",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07135986"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healt",
          "nctId": "NCT07135986",
          "phase": "PHASE3",
          "population": "Meningococcal Infection, Healthy Volunteers",
          "comparator": "",
          "expectedReadout": "2026-05-01",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-05-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07135986",
        "url": "https://clinicaltrials.gov/study/NCT07135986",
        "date": "2026-05-12"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-hz-su-vaccine-glaxosmithkline",
      "name": "HZ/su vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Varicella / Zoster",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2024-01-18",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05371080"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older",
          "nctId": "NCT05371080",
          "phase": "PHASE3",
          "population": "Herpes Zoster",
          "comparator": "",
          "expectedReadout": "2027-08-23",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-08-23 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05371080",
        "url": "https://clinicaltrials.gov/study/NCT05371080",
        "date": "2024-01-18"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxo",
      "name": "Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Meningococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-07-04",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04936685"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5",
          "nctId": "NCT04936685",
          "phase": "PHASE3",
          "population": "Meningococcal Immunisation, Healthy Volunteers",
          "comparator": "",
          "expectedReadout": "2023-03-09",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-03-09 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04936685",
        "url": "https://clinicaltrials.gov/study/NCT04936685",
        "date": "2025-07-04"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-bnt162b2-vaccine-biontech-se",
      "name": "BNT162b2 Vaccine",
      "developer": "BioNTech SE",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-04-13",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07300839"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age",
          "nctId": "NCT07300839",
          "phase": "PHASE3",
          "population": "COVID-19, SARS-COV-2 Infection",
          "comparator": "",
          "expectedReadout": "2026-07-31",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-07-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07300839",
        "url": "https://clinicaltrials.gov/study/NCT07300839",
        "date": "2026-04-13"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pcv21-vaccine-sanofi-pasteur-a-sanofi-company",
      "name": "RotaTeq",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Pneumococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-04-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06736041"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months o",
          "nctId": "NCT06736041",
          "phase": "PHASE3",
          "population": "Pneumococcal Immunization",
          "comparator": "",
          "expectedReadout": "2027-05-17",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-05-17 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06736041",
        "url": "https://clinicaltrials.gov/study/NCT06736041",
        "date": "2026-04-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-bnt162b2-2025-2026-formulation-biontech-se",
      "name": "BNT162b2 (2025/2026 formulation)",
      "developer": "BioNTech SE",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-02-11",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07222384"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A",
          "nctId": "NCT07222384",
          "phase": "PHASE3",
          "population": "COVID-19, SARS-COV-2 Infection",
          "comparator": "",
          "expectedReadout": "2026-07-31",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-07-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07222384",
        "url": "https://clinicaltrials.gov/study/NCT07222384",
        "date": "2026-02-11"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-c-difficile-vaccine-pfizer",
      "name": "C.difficile vaccine",
      "developer": "Pfizer",
      "targetDisease": "Clostridioides Difficile Associated Disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-26",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07282665"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older",
          "nctId": "NCT07282665",
          "phase": "PHASE3",
          "population": "Clostridioides Difficile Associated Disease",
          "comparator": "",
          "expectedReadout": "2028-12-11",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-12-11 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07282665",
        "url": "https://clinicaltrials.gov/study/NCT07282665",
        "date": "2026-05-26"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-v181-merck-sharp-dohme-llc",
      "name": "V181",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Dengue",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-07-10",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07013487"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)",
          "nctId": "NCT07013487",
          "phase": "PHASE3",
          "population": "Healthy",
          "comparator": "",
          "expectedReadout": "2031-10-24",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2031-10-24 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07013487",
        "url": "https://clinicaltrials.gov/study/NCT07013487",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-bivalent-enterovirus-vaccine-vero-cell-inactivated-sinovac-biote",
      "name": "Enterovirus Type 71 Vaccine (Vero Cell), Inactivated",
      "developer": "Sinovac Biotech Co., Ltd",
      "targetDisease": "Hand, Foot, and Mouth Disease（HFMD)",
      "platform": "Inactivated",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-01-01",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06734832"
      ],
      "trialSubEntries": [
        {
          "trialName": "Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)",
          "nctId": "NCT06734832",
          "phase": "PHASE3",
          "population": "Hand, Foot, and Mouth Disease（HFMD)",
          "comparator": "",
          "expectedReadout": "2025-11-30",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-11-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06734832",
        "url": "https://clinicaltrials.gov/study/NCT06734832",
        "date": "2025-01-01"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-chikv-vlp-vaccine-booster-bavarian-nordic",
      "name": "Placebo booster",
      "developer": "Bavarian Nordic",
      "targetDisease": "Chikungunya",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-04-03",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06007183"
      ],
      "trialSubEntries": [
        {
          "trialName": "Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination",
          "nctId": "NCT06007183",
          "phase": "PHASE3",
          "population": "Chikungunya Virus Infection",
          "comparator": "",
          "expectedReadout": "2028-04",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-04 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06007183",
        "url": "https://clinicaltrials.gov/study/NCT06007183",
        "date": "2025-04-03"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-durvalumab-medi4736-astrazeneca",
      "name": "Durvalumab (MEDI4736)",
      "developer": "AstraZeneca",
      "targetDisease": "Tuberculosis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-07-07",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03528694"
      ],
      "trialSubEntries": [
        {
          "trialName": "Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasiv",
          "nctId": "NCT03528694",
          "phase": "PHASE3",
          "population": "Non-muscle-invasive Bladder Cancer",
          "comparator": "",
          "expectedReadout": "2025-04-03",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-04-03 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03528694",
        "url": "https://clinicaltrials.gov/study/NCT03528694",
        "date": "2026-07-07"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-ofatumumab-novartis-pharmaceuticals",
      "name": "Ofatumumab",
      "developer": "Novartis Pharmaceuticals",
      "targetDisease": "Relapsing Multiple Sclerosis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03650114"
      ],
      "trialSubEntries": [
        {
          "trialName": "Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",
          "nctId": "NCT03650114",
          "phase": "PHASE3",
          "population": "Relapsing Multiple Sclerosis",
          "comparator": "",
          "expectedReadout": "2028-09-30",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-09-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03650114",
        "url": "https://clinicaltrials.gov/study/NCT03650114",
        "date": "2026-05-27"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pembrolizumab-merck-sharp-dohme-llc",
      "name": "BCG",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Tuberculosis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-01",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03711032"
      ],
      "trialSubEntries": [
        {
          "trialName": "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscl",
          "nctId": "NCT03711032",
          "phase": "PHASE3",
          "population": "High-risk Non-muscle Invasive Bladder Cancer",
          "comparator": "",
          "expectedReadout": "2026-07-31",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-07-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03711032",
        "url": "https://clinicaltrials.gov/study/NCT03711032",
        "date": "2026-05-01"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-tetravalent-dengue-vaccine-tdv-takeda",
      "name": "Tetravalent Dengue Vaccine (TDV)",
      "developer": "Takeda",
      "targetDisease": "Dengue",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-02-12",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07047521"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults",
          "nctId": "NCT07047521",
          "phase": "PHASE3",
          "population": "Dengue Fever",
          "comparator": "",
          "expectedReadout": "2026-08-30",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-08-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07047521",
        "url": "https://clinicaltrials.gov/study/NCT07047521",
        "date": "2026-02-12"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-rsv-mat-glaxosmithkline",
      "name": "RSV MAT",
      "developer": "GlaxoSmithKline",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2022-04-07",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05229068",
        "NCT04605159",
        "NCT04980391"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Partici",
          "nctId": "NCT05229068",
          "phase": "PHASE3",
          "population": "Respiratory Syncytial Virus Infections",
          "comparator": "",
          "expectedReadout": "2023-11-06",
          "status": "WITHDRAWN"
        },
        {
          "trialName": "A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women",
          "nctId": "NCT04605159",
          "phase": "PHASE3",
          "population": "Respiratory Syncytial Virus Infections",
          "comparator": "",
          "expectedReadout": "2023-06-14",
          "status": "TERMINATED"
        },
        {
          "trialName": "A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 t",
          "nctId": "NCT04980391",
          "phase": "PHASE3",
          "population": "Respiratory Syncytial Virus Infections",
          "comparator": "",
          "expectedReadout": "2023-05-30",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-11-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05229068",
        "url": "https://clinicaltrials.gov/study/NCT05229068",
        "date": "2022-04-07"
      },
      "additionalCitations": [
        {
          "label": "NCT04605159 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT04605159",
          "date": "2026-07-10"
        },
        {
          "label": "NCT04980391 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT04980391",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 3 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED, WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-cvncov-vaccine-curevac",
      "name": "CVnCoV Vaccine",
      "developer": "CureVac",
      "targetDisease": "COVID-19",
      "platform": "mRNA",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2021-08-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04838847",
        "NCT04860258"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Yo",
          "nctId": "NCT04838847",
          "phase": "PHASE3",
          "population": "Coronavirus, Covid19, SARS-CoV-2",
          "comparator": "",
          "expectedReadout": "2022-01",
          "status": "WITHDRAWN"
        },
        {
          "trialName": "COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults ",
          "nctId": "NCT04860258",
          "phase": "PHASE3",
          "population": "Coronavirus, Covid19, SARS-CoV-2",
          "comparator": "",
          "expectedReadout": "2021-09-21",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2022-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04838847",
        "url": "https://clinicaltrials.gov/study/NCT04838847",
        "date": "2021-08-20"
      },
      "additionalCitations": [
        {
          "label": "NCT04860258 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT04860258",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED, WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-tecemotide-merck-kgaa-darmstadt-germany",
      "name": "Tecemotide",
      "developer": "Merck KGaA, Darmstadt, Germany",
      "targetDisease": "Non-Small Cell Lung Cancer",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2016-10-26",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01015443",
        "NCT01423760"
      ],
      "trialSubEntries": [
        {
          "trialName": "Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population",
          "nctId": "NCT01015443",
          "phase": "PHASE3",
          "population": "Non-Small Cell Lung Cancer",
          "comparator": "",
          "expectedReadout": "2015-06",
          "status": "TERMINATED"
        },
        {
          "trialName": "Common Safety Follow-up Trial of Tecemotide (L-BLP25)",
          "nctId": "NCT01423760",
          "phase": "NA",
          "population": "Non-Small Cell Lung Cancer, Multiple Myeloma",
          "comparator": "",
          "expectedReadout": "2015-07",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2015-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01015443",
        "url": "https://clinicaltrials.gov/study/NCT01015443",
        "date": "2016-10-26"
      },
      "additionalCitations": [
        {
          "label": "NCT01423760 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT01423760",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-trivalent-inactivated-influenza-vaccine-high-dose-sanofi",
      "name": "Trivalent inactivated influenza vaccine",
      "developer": "Sanofi",
      "targetDisease": "Influenza",
      "platform": "Inactivated",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2012-08-01",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00976027"
      ],
      "trialSubEntries": [
        {
          "trialName": "Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older",
          "nctId": "NCT00976027",
          "phase": "PHASE3",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "2011-05",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2011-05 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00976027",
        "url": "https://clinicaltrials.gov/study/NCT00976027",
        "date": "2012-08-01"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-mva-bn-rsv-vaccine-bavarian-nordic",
      "name": "MVA-BN-RSV vaccine",
      "developer": "Bavarian Nordic",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2024-10-31",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05238025"
      ],
      "trialSubEntries": [
        {
          "trialName": "MVA-BN-RSV Vaccine Trial",
          "nctId": "NCT05238025",
          "phase": "PHASE3",
          "population": "Respiratory Syncytial Virus Infections",
          "comparator": "",
          "expectedReadout": "2023-06-29",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-06-29 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05238025",
        "url": "https://clinicaltrials.gov/study/NCT05238025",
        "date": "2024-10-31"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-measles-mumps-rubella-and-varicella-oka-merck-virus-vaccine-live",
      "name": "M-M-R™ II and Varivax™",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Measles / Mumps / Rubella",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2017-04-12",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00839917"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of ProQuad™ in Healthy Children in Korea (V221-023)",
          "nctId": "NCT00839917",
          "phase": "PHASE3",
          "population": "Measles, Mumps, Rubella",
          "comparator": "",
          "expectedReadout": "2008-05",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2008-05 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00839917",
        "url": "https://clinicaltrials.gov/study/NCT00839917",
        "date": "2017-04-12"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "mmr-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-quadrivalent-influenza-vaccine-high-dose-sanofi-pasteur-a-sanofi",
      "name": "Quadrivalent influenza vaccine, high-dose",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-12-24",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04544267"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Childr",
          "nctId": "NCT04544267",
          "phase": "PHASE3",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "2021-06-02",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2021-06-02 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04544267",
        "url": "https://clinicaltrials.gov/study/NCT04544267",
        "date": "2025-12-24"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-undecavalent-pneumococcal-protein-d-conjugate-vaccine-glaxosmith",
      "name": "undecavalent pneumococcal-protein D conjugate vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Pneumococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2017-03-23",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00119743"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine",
          "nctId": "NCT00119743",
          "phase": "PHASE3",
          "population": "Hepatitis A",
          "comparator": "",
          "expectedReadout": "2004-06",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2004-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00119743",
        "url": "https://clinicaltrials.gov/study/NCT00119743",
        "date": "2017-03-23"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-c",
      "name": "Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)",
      "developer": "CanSino Biologics Inc.",
      "targetDisease": "COVID-19",
      "platform": "Viral vector",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2023-06-15",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05169008"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adoles",
          "nctId": "NCT05169008",
          "phase": "PHASE3",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2023-01-13",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-01-13 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05169008",
        "url": "https://clinicaltrials.gov/study/NCT05169008",
        "date": "2023-06-15"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-ad26-protein-pref-rsv-vaccine-janssen-pharmaceutical-k-k",
      "name": "Ad26/protein preF RSV Vaccine",
      "developer": "Janssen Pharmaceutical K.K.",
      "targetDisease": "RSV",
      "platform": "Viral vector",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-05-23",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05242432"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention ",
          "nctId": "NCT05242432",
          "phase": "PHASE3",
          "population": "Respiratory Syncytial Virus Prevention",
          "comparator": "",
          "expectedReadout": "2023-03-20",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-03-20 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05242432",
        "url": "https://clinicaltrials.gov/study/NCT05242432",
        "date": "2025-05-23"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-quadrivalent-influenza-vaccine-split-virion-inactivated-high-dos",
      "name": "Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Influenza",
      "platform": "Inactivated",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-09-17",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04137887"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Q",
          "nctId": "NCT04137887",
          "phase": "PHASE3",
          "population": "Influenza (Healthy Volunteers)",
          "comparator": "",
          "expectedReadout": "2020-05-31",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2020-05-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04137887",
        "url": "https://clinicaltrials.gov/study/NCT04137887",
        "date": "2025-09-17"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-pandemrixtm-glaxosmithkline",
      "name": "PandemrixTM",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2016-10-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01160237"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM",
          "nctId": "NCT01160237",
          "phase": "PHASE3",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "2011-02",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2011-02 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01160237",
        "url": "https://clinicaltrials.gov/study/NCT01160237",
        "date": "2016-10-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-diphtheria-tetanus-pertussis-hepatitis-b-hib-vaccine-glaxosmithk",
      "name": "Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2016-10-07",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00316680"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age.",
          "nctId": "NCT00316680",
          "phase": "PHASE3",
          "population": "Haemophilus Influenzae Type b, Diphtheria, Tetanus",
          "comparator": "",
          "expectedReadout": "TBD",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "See linked ClinicalTrials.gov records for primary completion dates",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00316680",
        "url": "https://clinicaltrials.gov/study/NCT00316680",
        "date": "2016-10-07"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-hepatitis-b-vaccine-emergent-biosolutions",
      "name": "hepatitis B vaccine",
      "developer": "Emergent BioSolutions",
      "targetDisease": "Hepatitis B",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2024-03-18",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01311674"
      ],
      "trialSubEntries": [
        {
          "trialName": "Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)",
          "nctId": "NCT01311674",
          "phase": "PHASE3",
          "population": "Healthy Volunteers",
          "comparator": "",
          "expectedReadout": "2011-03-11",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2011-03-11 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01311674",
        "url": "https://clinicaltrials.gov/study/NCT01311674",
        "date": "2024-03-18"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hepatitis-b-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-recombinant-influenza-vaccine-riv4-sanofi-pasteur-a-sanofi-compa",
      "name": "Recombinant influenza vaccine (RIV4)",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Influenza",
      "platform": "Protein / subunit",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-09-09",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05513391"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV",
          "nctId": "NCT05513391",
          "phase": "PHASE3",
          "population": "Influenza Immunization",
          "comparator": "",
          "expectedReadout": "2023-10-03",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-10-03 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05513391",
        "url": "https://clinicaltrials.gov/study/NCT05513391",
        "date": "2025-09-09"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-pfizer-biontech-covid-19-vaccine-sunnybrook-health-sciences-cent",
      "name": "MODERNA SARS-CoV-2 Vaccine",
      "developer": "Sunnybrook Health Sciences Centre",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-02-19",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05022329"
      ],
      "trialSubEntries": [
        {
          "trialName": "COVID-19 Vaccine Boosters in Patients With CKD",
          "nctId": "NCT05022329",
          "phase": "PHASE2,PHASE3",
          "population": "Chronic Kidney Diseases, COVID-19",
          "comparator": "",
          "expectedReadout": "2022-05-11",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2022-05-11 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05022329",
        "url": "https://clinicaltrials.gov/study/NCT05022329",
        "date": "2025-02-19"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-gsk-pandemic-vaccine-gsk2340272a-glaxosmithkline",
      "name": "GSK pandemic vaccine GSK2340272A",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2018-09-21",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01014091"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Childre",
          "nctId": "NCT01014091",
          "phase": "PHASE3",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "2011-01-14",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2011-01-14 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01014091",
        "url": "https://clinicaltrials.gov/study/NCT01014091",
        "date": "2018-09-21"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-coformulated-cic-vaccine-novavax",
      "name": "Fluzone HD trivalent",
      "developer": "Novavax",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-03-11",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06482359"
      ],
      "trialSubEntries": [
        {
          "trialName": "Lot Consistency Study of COVID-19 and Influenza Combination Vaccine",
          "nctId": "NCT06482359",
          "phase": "PHASE2,PHASE3",
          "population": "COVID-19, Influenza",
          "comparator": "",
          "expectedReadout": "2025-11-16",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-11-16 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06482359",
        "url": "https://clinicaltrials.gov/study/NCT06482359",
        "date": "2025-03-11"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-tniv-1-and-matrix-m-adjuvant-novavax",
      "name": "tNIV 1 and Matrix-M Adjuvant",
      "developer": "Novavax",
      "targetDisease": "COVID-19",
      "platform": "Protein / subunit",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-03-11",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06485752"
      ],
      "trialSubEntries": [
        {
          "trialName": "Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine",
          "nctId": "NCT06485752",
          "phase": "PHASE2,PHASE3",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2025-02-04",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-02-04 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06485752",
        "url": "https://clinicaltrials.gov/study/NCT06485752",
        "date": "2025-03-11"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-janssen-vaccine-instituto-de-investigaci-n-marqu-s-de-valdecilla",
      "name": "Janssen vaccine",
      "developer": "Instituto de Investigación Marqués de Valdecilla",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2023-03-02",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05048940"
      ],
      "trialSubEntries": [
        {
          "trialName": "Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against ",
          "nctId": "NCT05048940",
          "phase": "PHASE3",
          "population": "Covid19",
          "comparator": "",
          "expectedReadout": "2021-09-01",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2021-09-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05048940",
        "url": "https://clinicaltrials.gov/study/NCT05048940",
        "date": "2023-03-02"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-varivax-vep-merck-sharp-dohme-llc",
      "name": "M-M-R™ II",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Varicella / Zoster",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2015-01-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01626794"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)",
          "nctId": "NCT01626794",
          "phase": "PHASE3",
          "population": "Varicella",
          "comparator": "",
          "expectedReadout": "2015-10",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2015-10 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01626794",
        "url": "https://clinicaltrials.gov/study/NCT01626794",
        "date": "2015-01-27"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-quadrivalent-human-papillomavirus-types-6-11-16-18-recombinant-v",
      "name": "Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "HPV",
      "platform": "Protein / subunit",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-03-03",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00733122"
      ],
      "trialSubEntries": [
        {
          "trialName": "Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)",
          "nctId": "NCT00733122",
          "phase": "PHASE3",
          "population": "HPV Infections",
          "comparator": "",
          "expectedReadout": "2013-10-01",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2013-10-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00733122",
        "url": "https://clinicaltrials.gov/study/NCT00733122",
        "date": "2025-03-03"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-pfizer-biontech-standard-dose-murdoch-childrens-research-institu",
      "name": "AstraZeneca Standard dose",
      "developer": "Murdoch Childrens Research Institute",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2024-03-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05387317"
      ],
      "trialSubEntries": [
        {
          "trialName": "Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)",
          "nctId": "NCT05387317",
          "phase": "PHASE3",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2025-01",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05387317",
        "url": "https://clinicaltrials.gov/study/NCT05387317",
        "date": "2024-03-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-gsk-s-candidate-influenza-vaccine-1562902a-glaxosmithkline",
      "name": "GSK's candidate influenza vaccine 1562902A",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2015-03-23",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00866580"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine",
          "nctId": "NCT00866580",
          "phase": "PHASE3",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "2011-07",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2011-07 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00866580",
        "url": "https://clinicaltrials.gov/study/NCT00866580",
        "date": "2015-03-23"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-v212-lot-1-merck-sharp-dohme-llc",
      "name": "V212 Lot 1",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Varicella / Zoster",
      "platform": "Inactivated",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2015-08-13",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02180295"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Viru",
          "nctId": "NCT02180295",
          "phase": "PHASE3",
          "population": "Herpes Zoster",
          "comparator": "",
          "expectedReadout": "2015-03",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2015-03 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02180295",
        "url": "https://clinicaltrials.gov/study/NCT02180295",
        "date": "2015-08-13"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-infanrix-ipv-hib-glaxosmithkline",
      "name": "Infanrix-IPV/Hib",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "Conjugate vaccine",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2017-12-26",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03128489"
      ],
      "trialSubEntries": [
        {
          "trialName": "Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and ",
          "nctId": "NCT03128489",
          "phase": "PHASE3",
          "population": "Diphtheria, Acellular Pertussis, Haemophilus Influenzae Type b",
          "comparator": "",
          "expectedReadout": "2018-08-01",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2018-08-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03128489",
        "url": "https://clinicaltrials.gov/study/NCT03128489",
        "date": "2017-12-26"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-vla2001-valneva-austria-gmbh",
      "name": "VLA2001",
      "developer": "Valneva Austria GmbH",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2022-11-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05298644"
      ],
      "trialSubEntries": [
        {
          "trialName": "COVID-19 Paediatric VLA2001-321 Study",
          "nctId": "NCT05298644",
          "phase": "PHASE2,PHASE3",
          "population": "SARS-CoV-2 Infection",
          "comparator": "",
          "expectedReadout": "2023-07-31",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-07-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05298644",
        "url": "https://clinicaltrials.gov/study/NCT05298644",
        "date": "2022-11-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-medium-dosage-covid-19-vaccine-inactivated-sinovac-research-and-",
      "name": "High-dosage COVID-19 Vaccine,Inactivated",
      "developer": "Sinovac Research and Development Co., Ltd.",
      "targetDisease": "COVID-19",
      "platform": "Inactivated",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2023-02-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05156632"
      ],
      "trialSubEntries": [
        {
          "trialName": "Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above",
          "nctId": "NCT05156632",
          "phase": "PHASE3",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2023-02-20",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-02-20 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05156632",
        "url": "https://clinicaltrials.gov/study/NCT05156632",
        "date": "2023-02-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-bivalent-recombinant-covid-19-vaccine-adenovirus-type-5-vector-c",
      "name": "mRNA-based COVID-19 vaccine",
      "developer": "CanSino Biologics Inc.",
      "targetDisease": "COVID-19",
      "platform": "mRNA",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2023-06-18",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05442684"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥1",
          "nctId": "NCT05442684",
          "phase": "PHASE3",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2023-03-30",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-03-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05442684",
        "url": "https://clinicaltrials.gov/study/NCT05442684",
        "date": "2023-06-18"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-rotavirus-vaccine-live-oral-pentavalent-merck-sharp-dohme-llc",
      "name": "Rotavirus Vaccine, Live, Oral, Pentavalent",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Rotavirus",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2015-10-09",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01003431"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With Rota",
          "nctId": "NCT01003431",
          "phase": "PHASE3",
          "population": "Rotavirus Gastroenteritis, Diphtheria, Tetanus",
          "comparator": "",
          "expectedReadout": "2010-08",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2010-08 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01003431",
        "url": "https://clinicaltrials.gov/study/NCT01003431",
        "date": "2015-10-09"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rotavirus-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-janssen-ad26-cov2-s-vaccine-mark-stegall",
      "name": "Janssen Ad26.CoV2.S Vaccine",
      "developer": "Mark Stegall",
      "targetDisease": "Kidney Transplant Recipient",
      "platform": "Viral vector",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-09-15",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05220397"
      ],
      "trialSubEntries": [
        {
          "trialName": "Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients",
          "nctId": "NCT05220397",
          "phase": "PHASE3",
          "population": "Kidney Transplant Recipient",
          "comparator": "",
          "expectedReadout": "2025-02-28",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-02-28 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05220397",
        "url": "https://clinicaltrials.gov/study/NCT05220397",
        "date": "2025-09-15"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-cyd-dengue-vaccine-sanofi-pasteur-a-sanofi-company",
      "name": "CYD Dengue Vaccine",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Dengue",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2022-03-25",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02992418"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects",
          "nctId": "NCT02992418",
          "phase": "PHASE3",
          "population": "Dengue Fever, Dengue Hemorrhagic Fever",
          "comparator": "",
          "expectedReadout": "2019-12-10",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2019-12-10 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02992418",
        "url": "https://clinicaltrials.gov/study/NCT02992418",
        "date": "2022-03-25"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-ad26-zebov-janssen-vaccines-prevention-b-v",
      "name": "Ad26.ZEBOV",
      "developer": "Janssen Vaccines & Prevention B.V.",
      "targetDisease": "Ebola",
      "platform": "Viral vector",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2024-01-02",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02661464"
      ],
      "trialSubEntries": [
        {
          "trialName": "Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo",
          "nctId": "NCT02661464",
          "phase": "PHASE3",
          "population": "Hemorrhagic Fever, Ebola",
          "comparator": "",
          "expectedReadout": "2021-12-13",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2021-12-13 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02661464",
        "url": "https://clinicaltrials.gov/study/NCT02661464",
        "date": "2024-01-02"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-c-difficile-toxoid-vaccine-sanofi-pasteur-a-sanofi-company",
      "name": "C. difficile Toxoid Vaccine",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Clostridium Difficile Infection",
      "platform": "Toxoid",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2022-03-28",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01887912"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection",
          "nctId": "NCT01887912",
          "phase": "PHASE3",
          "population": "Clostridium Difficile Infection",
          "comparator": "",
          "expectedReadout": "2018-06-12",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2018-06-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01887912",
        "url": "https://clinicaltrials.gov/study/NCT01887912",
        "date": "2022-03-28"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-lv305-immune-design-a-subsidiary-of-merck-co-inc-rahway-new-jers",
      "name": "G305",
      "developer": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "targetDisease": "Synovial Sarcoma",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2020-04-16",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03520959"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metasta",
          "nctId": "NCT03520959",
          "phase": "PHASE3",
          "population": "Synovial Sarcoma, Cancer, Soft Tissue Sarcoma",
          "comparator": "",
          "expectedReadout": "2018-11-20",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2018-11-20 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03520959",
        "url": "https://clinicaltrials.gov/study/NCT03520959",
        "date": "2020-04-16"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-gsk1572932a-antigen-specific-cancer-immunotherapeutic-glaxosmith",
      "name": "GSK1572932A Antigen-Specific Cancer Immunotherapeutic",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Lung Cancer, Non-Small Cell",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2020-12-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00480025"
      ],
      "trialSubEntries": [
        {
          "trialName": "GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer",
          "nctId": "NCT00480025",
          "phase": "PHASE3",
          "population": "Lung Cancer, Non-Small Cell",
          "comparator": "",
          "expectedReadout": "2013-12-06",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2013-12-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00480025",
        "url": "https://clinicaltrials.gov/study/NCT00480025",
        "date": "2020-12-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_3"
    },
    {
      "candidateId": "ctgov-yellow-fever-vaccine-produced-on-serum-free-vero-cells-sanofi-pa",
      "name": "Yellow fever vaccine",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Yellow fever",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2025-06-18",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04942210",
        "NCT05011123"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA",
          "nctId": "NCT04942210",
          "phase": "PHASE2",
          "population": "Yellow Fever, Healthy Volunteers",
          "comparator": "",
          "expectedReadout": "2022-06-24",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia",
          "nctId": "NCT05011123",
          "phase": "PHASE2",
          "population": "Yellow Fever",
          "comparator": "",
          "expectedReadout": "2022-05-23",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2022-06-24 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04942210",
        "url": "https://clinicaltrials.gov/study/NCT04942210",
        "date": "2025-06-18"
      },
      "additionalCitations": [
        {
          "label": "NCT05011123 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05011123",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "yellow-fever-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-acne-mrna-vaccine-sanofi-pasteur-a-sanofi-company",
      "name": "Acne mRNA vaccine",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Acne",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-05-05",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06316297",
        "NCT07013747"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne",
          "nctId": "NCT06316297",
          "phase": "PHASE1,PHASE2",
          "population": "Acne",
          "comparator": "",
          "expectedReadout": "2028-11-30",
          "status": "RECRUITING"
        },
        {
          "trialName": "Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne",
          "nctId": "NCT07013747",
          "phase": "PHASE1,PHASE2",
          "population": "Acne",
          "comparator": "",
          "expectedReadout": "2029-06-19",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-11-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06316297",
        "url": "https://clinicaltrials.gov/study/NCT06316297",
        "date": "2026-05-05"
      },
      "additionalCitations": [
        {
          "label": "NCT07013747 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07013747",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-1189-modernatx-inc",
      "name": "mRNA-1189",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "EBV",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-05-06",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05164094",
        "NCT07478952"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adult",
          "nctId": "NCT05164094",
          "phase": "PHASE1,PHASE2",
          "population": "Epstein-Barr Virus Infection",
          "comparator": "",
          "expectedReadout": "2026-10-05",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age",
          "nctId": "NCT07478952",
          "phase": "PHASE1",
          "population": "Epstein-Barr Virus",
          "comparator": "",
          "expectedReadout": "2027-05-15",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-10-05 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05164094",
        "url": "https://clinicaltrials.gov/study/NCT05164094",
        "date": "2026-05-06"
      },
      "additionalCitations": [
        {
          "label": "NCT07478952 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07478952",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-ped-hz-su-glaxosmithkline",
      "name": "PED-HZ/su",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Varicella / Zoster",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-02-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04006808"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney",
          "nctId": "NCT04006808",
          "phase": "PHASE1,PHASE2",
          "population": "Herpes Zoster",
          "comparator": "",
          "expectedReadout": "2026-05-01",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-05-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04006808",
        "url": "https://clinicaltrials.gov/study/NCT04006808",
        "date": "2026-02-27"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-vaccine-candidate-1-pfizer",
      "name": "TIV1 or TIV2",
      "developer": "Pfizer",
      "targetDisease": "Influenza",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-05-06",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07431853"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Learn About mRNA Vaccines Against Influenza in Adults",
          "nctId": "NCT07431853",
          "phase": "PHASE2",
          "population": "Healthy Adults",
          "comparator": "",
          "expectedReadout": "2027-06-22",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-06-22 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07431853",
        "url": "https://clinicaltrials.gov/study/NCT07431853",
        "date": "2026-05-06"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-low-dose-of-ints-tcv-glaxosmithkline",
      "name": "TYPHIBEV",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Typhoid",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-04-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07286370"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal S",
          "nctId": "NCT07286370",
          "phase": "PHASE2",
          "population": "Salmonella Infections",
          "comparator": "",
          "expectedReadout": "2028-04-27",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-04-27 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07286370",
        "url": "https://clinicaltrials.gov/study/NCT07286370",
        "date": "2026-04-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "typhoid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-recombinant-trivalent-poliomyelitis-vaccine-sf-rvn-cell-vlp-poli",
      "name": "VLP-Polio medium dose",
      "developer": "CanSino Biologics Inc.",
      "targetDisease": "Polio",
      "platform": "Virus-like particle",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2025-07-04",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06577298"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers",
          "nctId": "NCT06577298",
          "phase": "PHASE1,PHASE2",
          "population": "Poliomyelitis",
          "comparator": "",
          "expectedReadout": "2026-10",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-10 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06577298",
        "url": "https://clinicaltrials.gov/study/NCT06577298",
        "date": "2025-07-04"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "polio-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-rsv-hmpv-v-low-dose-vaccine-glaxosmithkline",
      "name": "hMPV_Y low dose vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-07-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07628049"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults",
          "nctId": "NCT07628049",
          "phase": "PHASE1,PHASE2",
          "population": "Respiratory Syncytial Virus Infections+Metapneumovirus",
          "comparator": "",
          "expectedReadout": "2029-04-05",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2029-04-05 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07628049",
        "url": "https://clinicaltrials.gov/study/NCT07628049",
        "date": "2026-07-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-oral-hexavalent-reassortant-rotavirus-attenuated-live-vaccine-si",
      "name": "Oral hexavalent reassortant rotavirus attenuated live vaccine",
      "developer": "Sinovac Life Sciences Co., Ltd.",
      "targetDisease": "Rotavirus",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2025-08-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06967272"
      ],
      "trialSubEntries": [
        {
          "trialName": "PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)",
          "nctId": "NCT06967272",
          "phase": "PHASE2",
          "population": "Rotavirus Gastroenteritis",
          "comparator": "",
          "expectedReadout": "2026-06-15",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-06-15 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06967272",
        "url": "https://clinicaltrials.gov/study/NCT06967272",
        "date": "2025-08-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rotavirus-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-adjuvanted-rsvpref3-vaccine-glaxosmithkline",
      "name": "Adjuvanted RSVPreF3 vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-03-06",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07092865"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and th",
          "nctId": "NCT07092865",
          "phase": "PHASE2",
          "population": "Respiratory Syncytial Virus Infections",
          "comparator": "",
          "expectedReadout": "2027-01-12",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-01-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07092865",
        "url": "https://clinicaltrials.gov/study/NCT07092865",
        "date": "2026-03-06"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-low-dose-experimental-vaccine-sinovac-biotech-co-ltd",
      "name": "Active-controlled vaccine A",
      "developer": "Sinovac Biotech Co., Ltd",
      "targetDisease": "Varicella / Zoster",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-02-10",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07400003"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine",
          "nctId": "NCT07400003",
          "phase": "PHASE1,PHASE2",
          "population": "Herpes Zoster, mRNA Vaccine",
          "comparator": "",
          "expectedReadout": "2026-05-31",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-05-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07400003",
        "url": "https://clinicaltrials.gov/study/NCT07400003",
        "date": "2026-02-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-24-valent-pneumococcal-polysaccharide-conjugate-vaccine-crm197-t",
      "name": "PCV24 vaccine (dose H)",
      "developer": "CanSino Biologics Inc.",
      "targetDisease": "Pneumococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-05-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07600983"
      ],
      "trialSubEntries": [
        {
          "trialName": "Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)",
          "nctId": "NCT07600983",
          "phase": "PHASE1,PHASE2",
          "population": "Streptococcus Pneumoniae Infection",
          "comparator": "",
          "expectedReadout": "2026-11-24",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-11-24 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07600983",
        "url": "https://clinicaltrials.gov/study/NCT07600983",
        "date": "2026-05-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pentavalent-meningococcal-abcyw-vaccine-sanofi-pasteur-a-sanofi-",
      "name": "MenACYW conjugate vaccine",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Meningococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-01-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06647407"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in",
          "nctId": "NCT06647407",
          "phase": "PHASE1,PHASE2",
          "population": "Meningococcal Immunization, Healthy Volunteers",
          "comparator": "",
          "expectedReadout": "2027-05-17",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-05-17 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06647407",
        "url": "https://clinicaltrials.gov/study/NCT06647407",
        "date": "2026-01-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-investigational-hmpv-rsv-vaccine-sanofi-pasteur-a-sanofi-company",
      "name": "Licensed RSV Vaccine",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "RSV",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2025-12-11",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06686654"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle",
          "nctId": "NCT06686654",
          "phase": "PHASE1,PHASE2",
          "population": "Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization",
          "comparator": "",
          "expectedReadout": "2027-01-18",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-01-18 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06686654",
        "url": "https://clinicaltrials.gov/study/NCT06686654",
        "date": "2025-12-11"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-z-1018-dynavax-technologies-corporation",
      "name": "Z-1018",
      "developer": "Dynavax Technologies Corporation",
      "targetDisease": "Varicella / Zoster",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-05-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06569823"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 5",
          "nctId": "NCT06569823",
          "phase": "PHASE1,PHASE2",
          "population": "Shingles, Herpes Zoster, Vaccine-Preventable Diseases",
          "comparator": "",
          "expectedReadout": "2027-11",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-11 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06569823",
        "url": "https://clinicaltrials.gov/study/NCT06569823",
        "date": "2026-05-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-ints-gmma-dose-c-glaxosmithkline",
      "name": "MenACWY",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Typhoid",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-05-19",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06213506"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal S",
          "nctId": "NCT06213506",
          "phase": "PHASE2",
          "population": "Salmonella Infections",
          "comparator": "",
          "expectedReadout": "2026-09-30",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-09-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06213506",
        "url": "https://clinicaltrials.gov/study/NCT06213506",
        "date": "2026-05-19"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "typhoid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pandemic-flu-h5-ha-mrna-sd2-vaccine-sanofi",
      "name": "Pandemic flu H5 HA mRNA SD2 vaccine",
      "developer": "Sanofi",
      "targetDisease": "Influenza",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-01-16",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06907511"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate ",
          "nctId": "NCT06907511",
          "phase": "PHASE1,PHASE2",
          "population": "Pandemic Influenza Immunization, Healthy Volunteers",
          "comparator": "",
          "expectedReadout": "2026-12-01",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-12-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06907511",
        "url": "https://clinicaltrials.gov/study/NCT06907511",
        "date": "2026-01-16"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-azd4117-astrazeneca",
      "name": "AZD4117",
      "developer": "AstraZeneca",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-03-23",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07128615"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)",
          "nctId": "NCT07128615",
          "phase": "PHASE1,PHASE2",
          "population": "Influenza A",
          "comparator": "",
          "expectedReadout": "2026-01-28",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-01-28 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07128615",
        "url": "https://clinicaltrials.gov/study/NCT07128615",
        "date": "2026-03-23"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-0-5-ml-of-the-low-dose-vax-31-vaxcyte-inc",
      "name": "0.5 mL of the low dose VAX-31",
      "developer": "Vaxcyte, Inc.",
      "targetDisease": "Pneumococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-05-15",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06720038"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants",
          "nctId": "NCT06720038",
          "phase": "PHASE2",
          "population": "Pneumococcal Vaccines",
          "comparator": "",
          "expectedReadout": "2027-12",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06720038",
        "url": "https://clinicaltrials.gov/study/NCT06720038",
        "date": "2026-05-15"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-flu-mrna-formulation-b1-glaxosmithkline",
      "name": "Flu mRNA(Formulation A)",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-03-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07204964"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above",
          "nctId": "NCT07204964",
          "phase": "PHASE2",
          "population": "Influenza, Human",
          "comparator": "",
          "expectedReadout": "2026-07-31",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-07-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07204964",
        "url": "https://clinicaltrials.gov/study/NCT07204964",
        "date": "2026-03-27"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-1468-modernatx-inc",
      "name": "mRNA-1468",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "Varicella / Zoster",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2025-08-13",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05701800"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age",
          "nctId": "NCT05701800",
          "phase": "PHASE1,PHASE2",
          "population": "Herpes Zoster",
          "comparator": "",
          "expectedReadout": "2026-06-30",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-06-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05701800",
        "url": "https://clinicaltrials.gov/study/NCT05701800",
        "date": "2025-08-13"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-1195-modernatx-inc",
      "name": "mRNA-1195",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "Multiple Sclerosis",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-06-15",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06735248"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 1",
          "nctId": "NCT06735248",
          "phase": "PHASE2",
          "population": "Multiple Sclerosis",
          "comparator": "",
          "expectedReadout": "2029-01-08",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2029-01-08 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06735248",
        "url": "https://clinicaltrials.gov/study/NCT06735248",
        "date": "2026-06-15"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-bnt166a-biontech-se",
      "name": "BNT166a",
      "developer": "BioNTech SE",
      "targetDisease": "Mpox",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-07-09",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07379580"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA",
          "nctId": "NCT07379580",
          "phase": "PHASE2",
          "population": "Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection",
          "comparator": "",
          "expectedReadout": "2027-06",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07379580",
        "url": "https://clinicaltrials.gov/study/NCT07379580",
        "date": "2026-07-09"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-rf1v-1018-dynavax-technologies-corporation",
      "name": "rF1V-1018",
      "developer": "Dynavax Technologies Corporation",
      "targetDisease": "Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-06-18",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07207408"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age",
          "nctId": "NCT07207408",
          "phase": "PHASE2",
          "population": "Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis",
          "comparator": "",
          "expectedReadout": "2027-01-29",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-01-29 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07207408",
        "url": "https://clinicaltrials.gov/study/NCT07207408",
        "date": "2026-06-18"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-chlamydia-mrna-vaccine-sanofi",
      "name": "Chlamydia mRNA Vaccine",
      "developer": "Sanofi",
      "targetDisease": "Chlamydia Trachomatis Immunization",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-04-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06891417"
      ],
      "trialSubEntries": [
        {
          "trialName": "Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years",
          "nctId": "NCT06891417",
          "phase": "PHASE1,PHASE2",
          "population": "Chlamydia Trachomatis Immunization",
          "comparator": "",
          "expectedReadout": "2028-01-03",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-01-03 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06891417",
        "url": "https://clinicaltrials.gov/study/NCT06891417",
        "date": "2026-04-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-1982-modernatx-inc",
      "name": "mRNA-1982",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "Lyme disease",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-05-28",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07561294"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Parti",
          "nctId": "NCT07561294",
          "phase": "PHASE2",
          "population": "Lyme Disease",
          "comparator": "",
          "expectedReadout": "2028-11-09",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-11-09 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07561294",
        "url": "https://clinicaltrials.gov/study/NCT07561294",
        "date": "2026-05-28"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-as01-adjuvant-0-5-ml-intramuscular-singapore-general-hospital",
      "name": "YF17D (Stamaril, Sanofi-Pasteur)",
      "developer": "Singapore General Hospital",
      "targetDisease": "Immune System Responses and Trained Immunity After AS01 Administration",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-06-15",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07527247"
      ],
      "trialSubEntries": [
        {
          "trialName": "Improving Vaccine Protection for Adults",
          "nctId": "NCT07527247",
          "phase": "PHASE2",
          "population": "Immune System Responses and Trained Immunity After AS01 Administration, Healthy Adult",
          "comparator": "",
          "expectedReadout": "2029-02-28",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2029-02-28 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07527247",
        "url": "https://clinicaltrials.gov/study/NCT07527247",
        "date": "2026-06-15"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-rts-s-as01e-vaccine-glaxosmithkline",
      "name": "RTS,S/AS01E vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Malaria",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2025-09-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07036159"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months",
          "nctId": "NCT07036159",
          "phase": "PHASE2",
          "population": "Malaria",
          "comparator": "",
          "expectedReadout": "2027-04-23",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-04-23 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07036159",
        "url": "https://clinicaltrials.gov/study/NCT07036159",
        "date": "2025-09-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-zigakibart-novartis-pharmaceuticals",
      "name": "zigakibart",
      "developer": "Novartis Pharmaceuticals",
      "targetDisease": "Immunoglobulin A Nephropathy (IgAN)",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-06-23",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07146906"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Assess the Effects of Zigakibart on IgA Nephropathy.",
          "nctId": "NCT07146906",
          "phase": "PHASE2",
          "population": "Immunoglobulin A Nephropathy (IgAN)",
          "comparator": "",
          "expectedReadout": "2030-07-12",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2030-07-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07146906",
        "url": "https://clinicaltrials.gov/study/NCT07146906",
        "date": "2026-06-23"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-influenza-vaccine-sequiris-fluad-quad-central-adelaide-local-hea",
      "name": "RSV vaccine (Pfizer Abrysvo)",
      "developer": "Central Adelaide Local Health Network Incorporated",
      "targetDisease": "Vaccine Immune Response",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-05-14",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07587801"
      ],
      "trialSubEntries": [
        {
          "trialName": "Vaccination Response Modulation With a Targeted Rapamycin Protocol Study",
          "nctId": "NCT07587801",
          "phase": "PHASE2",
          "population": "Vaccine Immune Response, Haemodialysis Patients, Older Adults",
          "comparator": "",
          "expectedReadout": "2026-07",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-07 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07587801",
        "url": "https://clinicaltrials.gov/study/NCT07587801",
        "date": "2026-05-14"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-altsonflex1-2-3-glaxosmithkline",
      "name": "Menveo",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Diarrhoea",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-01-06",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07320716"
      ],
      "trialSubEntries": [
        {
          "trialName": "Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children",
          "nctId": "NCT07320716",
          "phase": "PHASE2",
          "population": "Diarrhoea",
          "comparator": "",
          "expectedReadout": "2028-10-31",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-10-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07320716",
        "url": "https://clinicaltrials.gov/study/NCT07320716",
        "date": "2026-01-06"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-v540a-2-merck-sharp-dohme-llc",
      "name": "V540A-2",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Healthy",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-02-19",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07224477"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Clinical Study of V540A in Healthy Female Participants (V540A-005)",
          "nctId": "NCT07224477",
          "phase": "PHASE2",
          "population": "Healthy",
          "comparator": "",
          "expectedReadout": "2028-04-04",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-04-04 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07224477",
        "url": "https://clinicaltrials.gov/study/NCT07224477",
        "date": "2026-02-19"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pfizer-biontech-mrna-covid-19-vaccine-university-of-florida",
      "name": "Pfizer-BioNTech mRNA COVID-19 vaccine",
      "developer": "University of Florida",
      "targetDisease": "Stage 4 NSCLC",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-06-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07597070"
      ],
      "trialSubEntries": [
        {
          "trialName": "Universal Immunization to Fortify Immunotherapy Efficacy and Response",
          "nctId": "NCT07597070",
          "phase": "PHASE2",
          "population": "Stage 4 NSCLC",
          "comparator": "",
          "expectedReadout": "2035-03",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2035-03 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07597070",
        "url": "https://clinicaltrials.gov/study/NCT07597070",
        "date": "2026-06-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mtbvac-bharat-biotech-international-limited",
      "name": "MTBVAC",
      "developer": "Bharat Biotech International Limited",
      "targetDisease": "Tuberculosis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-04-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06997367"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV16",
          "nctId": "NCT06997367",
          "phase": "PHASE2",
          "population": "Tuberculosis (TB)",
          "comparator": "",
          "expectedReadout": "2025-09-01",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-09-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06997367",
        "url": "https://clinicaltrials.gov/study/NCT06997367",
        "date": "2026-04-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mva-bn-wev-bavarian-nordic",
      "name": "MVA-BN-WEV",
      "developer": "Bavarian Nordic",
      "targetDisease": "Encephalitis",
      "platform": "Protein / subunit",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2025-10-01",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06899802"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine",
          "nctId": "NCT06899802",
          "phase": "PHASE2",
          "population": "Encephalitis",
          "comparator": "",
          "expectedReadout": "2027-02",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-02 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06899802",
        "url": "https://clinicaltrials.gov/study/NCT06899802",
        "date": "2025-10-01"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-bnt164a1-biontech-se",
      "name": "BNT164a1",
      "developer": "BioNTech SE",
      "targetDisease": "Tuberculosis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-03-18",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05547464"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Va",
          "nctId": "NCT05547464",
          "phase": "PHASE1,PHASE2",
          "population": "Tuberculosis",
          "comparator": "",
          "expectedReadout": "2026-03-12",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-03-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05547464",
        "url": "https://clinicaltrials.gov/study/NCT05547464",
        "date": "2026-03-18"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-c-difficile-vaccine-previously-studied-formulation-pfizer",
      "name": "C. difficile vaccine formulation 1.",
      "developer": "Pfizer",
      "targetDisease": "Clostridoides Difficile Associated Disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-04-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05805826"
      ],
      "trialSubEntries": [
        {
          "trialName": "To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults",
          "nctId": "NCT05805826",
          "phase": "PHASE1,PHASE2",
          "population": "Clostridoides Difficile Associated Disease",
          "comparator": "",
          "expectedReadout": "2031-06-19",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2031-06-19 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05805826",
        "url": "https://clinicaltrials.gov/study/NCT05805826",
        "date": "2026-04-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-10-g-of-r21-with-50-g-matrix-m1-serum-institute-of-india-pvt-ltd",
      "name": "RABIVAX-S",
      "developer": "Serum Institute of India Pvt. Ltd.",
      "targetDisease": "Malaria",
      "platform": "Protein / subunit",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-07-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07147400"
      ],
      "trialSubEntries": [
        {
          "trialName": "Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults",
          "nctId": "NCT07147400",
          "phase": "PHASE2",
          "population": "Prevention of Malaria Transmission and Clinical Malaria",
          "comparator": "",
          "expectedReadout": "2027-11",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-11 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07147400",
        "url": "https://clinicaltrials.gov/study/NCT07147400",
        "date": "2026-07-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-4157-modernatx-inc",
      "name": "mRNA-4157",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "Melanoma",
      "platform": "mRNA",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2025-12-03",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03897881"
      ],
      "trialSubEntries": [
        {
          "trialName": "An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants",
          "nctId": "NCT03897881",
          "phase": "PHASE2",
          "population": "Melanoma",
          "comparator": "",
          "expectedReadout": "2032-11-30",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2032-11-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03897881",
        "url": "https://clinicaltrials.gov/study/NCT03897881",
        "date": "2025-12-03"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-jynneos-bavarian-nordic",
      "name": "Jynneos",
      "developer": "Bavarian Nordic",
      "targetDisease": "Mpox",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_2",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_2",
          "date": "2026-04-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07199569"
      ],
      "trialSubEntries": [
        {
          "trialName": "Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells",
          "nctId": "NCT07199569",
          "phase": "PHASE2",
          "population": "Monkeypox (Mpox)",
          "comparator": "",
          "expectedReadout": "2026-11-30",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-11-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07199569",
        "url": "https://clinicaltrials.gov/study/NCT07199569",
        "date": "2026-04-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-cv9104-curevac",
      "name": "CV9104",
      "developer": "CureVac",
      "targetDisease": "Prostate Carcinoma",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2016-06-13",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02140138",
        "NCT01817738"
      ],
      "trialSubEntries": [
        {
          "trialName": "An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Can",
          "nctId": "NCT02140138",
          "phase": "PHASE2",
          "population": "Prostate Carcinoma",
          "comparator": "",
          "expectedReadout": "2016-04",
          "status": "TERMINATED"
        },
        {
          "trialName": "Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer",
          "nctId": "NCT01817738",
          "phase": "PHASE1,PHASE2",
          "population": "Prostate Cancer",
          "comparator": "",
          "expectedReadout": "2016-08",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2016-04 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02140138",
        "url": "https://clinicaltrials.gov/study/NCT02140138",
        "date": "2016-06-13"
      },
      "additionalCitations": [
        {
          "label": "NCT01817738 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT01817738",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-moderna-mrna-1273-national-institute-of-allergy-and-infectious-d",
      "name": "Moderna mRNA-1273",
      "developer": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "targetDisease": "COVID-19",
      "platform": "mRNA",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2026-06-10",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05000216"
      ],
      "trialSubEntries": [
        {
          "trialName": "COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders",
          "nctId": "NCT05000216",
          "phase": "PHASE2",
          "population": "Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris",
          "comparator": "",
          "expectedReadout": "2023-06-22",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-06-22 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05000216",
        "url": "https://clinicaltrials.gov/study/NCT05000216",
        "date": "2026-06-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-meningococcal-b-rlp2086-vaccine-pfizer",
      "name": "meningococcal B rLP2086 vaccine",
      "developer": "Pfizer",
      "targetDisease": "Meningococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2014-11-26",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00798304"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants",
          "nctId": "NCT00798304",
          "phase": "PHASE2",
          "population": "Meningitis, Meningococcal",
          "comparator": "",
          "expectedReadout": "2009-06",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2009-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00798304",
        "url": "https://clinicaltrials.gov/study/NCT00798304",
        "date": "2014-11-26"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-equine-covid-19-antiserum-bharat-serums-and-vaccines-limited",
      "name": "Equine COVID-19 Antiserum",
      "developer": "Bharat Serums and Vaccines Limited",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2022-10-14",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04834908"
      ],
      "trialSubEntries": [
        {
          "trialName": "Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection",
          "nctId": "NCT04834908",
          "phase": "PHASE1,PHASE2",
          "population": "SARS-CoV-2 Infection",
          "comparator": "",
          "expectedReadout": "2022-05-25",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2022-05-25 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04834908",
        "url": "https://clinicaltrials.gov/study/NCT04834908",
        "date": "2022-10-14"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-v591-merck-sharp-dohme-llc",
      "name": "V591",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2021-12-23",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04498247"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)",
          "nctId": "NCT04498247",
          "phase": "PHASE1,PHASE2",
          "population": "Coronavirus Disease (COVID-19)",
          "comparator": "",
          "expectedReadout": "2021-03-05",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2021-03-05 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04498247",
        "url": "https://clinicaltrials.gov/study/NCT04498247",
        "date": "2021-12-23"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-multivalent-pfizer",
      "name": "Prevnar 13",
      "developer": "Pfizer",
      "targetDisease": "Pneumococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2021-11-30",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03550313"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy I",
          "nctId": "NCT03550313",
          "phase": "PHASE2",
          "population": "Pneumococcal Infections",
          "comparator": "",
          "expectedReadout": "2020-11-05",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2020-11-05 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03550313",
        "url": "https://clinicaltrials.gov/study/NCT03550313",
        "date": "2021-11-30"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-chad155-hii-hbv-low-dose-formulation-glaxosmithkline",
      "name": "MVA-HBV low dose formulation",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Hepatitis B",
      "platform": "Viral vector",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2026-02-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03866187"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A",
          "nctId": "NCT03866187",
          "phase": "PHASE1,PHASE2",
          "population": "Hepatitis B, Chronic",
          "comparator": "",
          "expectedReadout": "2024-10-07",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2024-10-07 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03866187",
        "url": "https://clinicaltrials.gov/study/NCT03866187",
        "date": "2026-02-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hepatitis-b-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-gsk2202083a-vaccine-glaxosmithkline",
      "name": "GSK2202083A vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2018-06-06",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00871741"
      ],
      "trialSubEntries": [
        {
          "trialName": "Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.",
          "nctId": "NCT00871741",
          "phase": "PHASE2",
          "population": "Tetanus, Poliomyelitis, Neisseria Meningitidis",
          "comparator": "",
          "expectedReadout": "2009-06-25",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2009-06-25 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00871741",
        "url": "https://clinicaltrials.gov/study/NCT00871741",
        "date": "2018-06-06"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-rsv-pref-based-vaccine-janssen-vaccines-prevention-b-v",
      "name": "RSV preF-based Vaccine",
      "developer": "Janssen Vaccines & Prevention B.V.",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-05-25",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05327816"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Year",
          "nctId": "NCT05327816",
          "phase": "PHASE1,PHASE2",
          "population": "Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention",
          "comparator": "",
          "expectedReadout": "2023-01-16",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-01-16 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05327816",
        "url": "https://clinicaltrials.gov/study/NCT05327816",
        "date": "2025-05-25"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-menabcwy-pfizer",
      "name": "Bexsero",
      "developer": "Pfizer",
      "targetDisease": "Meningococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2024-03-25",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04645966"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants",
          "nctId": "NCT04645966",
          "phase": "PHASE2",
          "population": "Meningococcal Vaccine",
          "comparator": "",
          "expectedReadout": "2022-09-15",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2022-09-15 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04645966",
        "url": "https://clinicaltrials.gov/study/NCT04645966",
        "date": "2024-03-25"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-sabin-based-inactivated-poliomyelitis-vaccine-sipv-takeda",
      "name": "Reference IPV",
      "developer": "Takeda",
      "targetDisease": "Polio",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2020-01-31",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03092791"
      ],
      "trialSubEntries": [
        {
          "trialName": "IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults",
          "nctId": "NCT03092791",
          "phase": "PHASE1,PHASE2",
          "population": "Poliomyelitis",
          "comparator": "",
          "expectedReadout": "2018-04-03",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2018-04-03 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03092791",
        "url": "https://clinicaltrials.gov/study/NCT03092791",
        "date": "2020-01-31"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "polio-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-nanoflu-quad-niv-novavax",
      "name": "Fluzone HD",
      "developer": "Novavax",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2022-11-04",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03658629"
      ],
      "trialSubEntries": [
        {
          "trialName": "Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults",
          "nctId": "NCT03658629",
          "phase": "PHASE2",
          "population": "Influenza, Human",
          "comparator": "",
          "expectedReadout": "2019-04-26",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2019-04-26 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03658629",
        "url": "https://clinicaltrials.gov/study/NCT03658629",
        "date": "2022-11-04"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-gsk2340272a-gsk-biologicals-investigational-influenza-pandemic-v",
      "name": "GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2019-02-15",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01003418"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children",
          "nctId": "NCT01003418",
          "phase": "PHASE2",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "2010-11-25",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2010-11-25 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01003418",
        "url": "https://clinicaltrials.gov/study/NCT01003418",
        "date": "2019-02-15"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-mrna-1273-214-modernatx-inc",
      "name": "mRNA-1273.214",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "COVID-19",
      "platform": "mRNA",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-11-26",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05584202"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infant",
          "nctId": "NCT05584202",
          "phase": "PHASE2",
          "population": "SARS-CoV-2",
          "comparator": "",
          "expectedReadout": "2024-11-15",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2024-11-15 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05584202",
        "url": "https://clinicaltrials.gov/study/NCT05584202",
        "date": "2025-11-26"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-gsk-bio-s-influenza-vaccine-gsk2584786a-different-formulations-g",
      "name": "GSK Bio's influenza vaccine GSK2584786A, different formulations",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2020-10-30",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01195779"
      ],
      "trialSubEntries": [
        {
          "trialName": "Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children",
          "nctId": "NCT01195779",
          "phase": "PHASE2",
          "population": "Influenza, Influenza Vaccines",
          "comparator": "",
          "expectedReadout": "2011-03-22",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2011-03-22 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01195779",
        "url": "https://clinicaltrials.gov/study/NCT01195779",
        "date": "2020-10-30"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-sars-cov-2-mrna-vaccine-formulation-1-sanofi-pasteur-a-sanofi-co",
      "name": "Placebo (0.9% normal saline)",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "COVID-19",
      "platform": "mRNA",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-09-11",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04798027"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older",
          "nctId": "NCT04798027",
          "phase": "PHASE1,PHASE2",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2022-06-27",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2022-06-27 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04798027",
        "url": "https://clinicaltrials.gov/study/NCT04798027",
        "date": "2025-09-11"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-1018-iss-hbsag-single-dynavax-technologies-corporation",
      "name": "1018 ISS-HBsAg-Single",
      "developer": "Dynavax Technologies Corporation",
      "targetDisease": "Hepatitis B",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2019-03-26",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00498212"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal D",
          "nctId": "NCT00498212",
          "phase": "PHASE2",
          "population": "Hepatitis B",
          "comparator": "",
          "expectedReadout": "2008-08",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2008-08 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00498212",
        "url": "https://clinicaltrials.gov/study/NCT00498212",
        "date": "2019-03-26"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hepatitis-b-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-v502-merck-sharp-dohme-llc",
      "name": "V502",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "HPV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2015-06-19",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00365443"
      ],
      "trialSubEntries": [
        {
          "trialName": "Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)",
          "nctId": "NCT00365443",
          "phase": "PHASE2",
          "population": "Cervical Cancer, Condylomata Acuminata",
          "comparator": "",
          "expectedReadout": "TBD",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "See linked ClinicalTrials.gov records for primary completion dates",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00365443",
        "url": "https://clinicaltrials.gov/study/NCT00365443",
        "date": "2015-06-19"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-vaccine-sanofi-a-h1n1-15-ug-trivalent-instituto-nacional-de-salu",
      "name": "Vaccine Sanofi A(H1N1) 7.5 ug",
      "developer": "Instituto Nacional de Salud Publica, Mexico",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2012-04-02",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00989274"
      ],
      "trialSubEntries": [
        {
          "trialName": "Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1",
          "nctId": "NCT00989274",
          "phase": "PHASE2",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "2010-06",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2010-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00989274",
        "url": "https://clinicaltrials.gov/study/NCT00989274",
        "date": "2012-04-02"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-influenza-surface-antigen-inactivated-vaccine-novartis",
      "name": "influenza surface antigen inactivated vaccine",
      "developer": "Novartis",
      "targetDisease": "Influenza",
      "platform": "Inactivated",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2017-04-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00342940"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Sub",
          "nctId": "NCT00342940",
          "phase": "PHASE2",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "TBD",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "See linked ClinicalTrials.gov records for primary completion dates",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00342940",
        "url": "https://clinicaltrials.gov/study/NCT00342940",
        "date": "2017-04-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-gsk-influenza-virus-h5n1-vaccine-1557484a-glaxosmithkline",
      "name": "GSK influenza virus H5N1 vaccine 1557484A",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2015-03-23",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01045564"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure",
          "nctId": "NCT01045564",
          "phase": "PHASE2",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "2013-02",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2013-02 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01045564",
        "url": "https://clinicaltrials.gov/study/NCT01045564",
        "date": "2015-03-23"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-rsv-vaccine-gsk3003891a-formulation-1-glaxosmithkline",
      "name": "RSV vaccine (GSK3003891A) formulation 1",
      "developer": "GlaxoSmithKline",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2018-10-15",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03191383"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory ",
          "nctId": "NCT03191383",
          "phase": "PHASE2",
          "population": "Respiratory Syncytial Virus Infections",
          "comparator": "",
          "expectedReadout": "2017-07-14",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2017-07-14 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03191383",
        "url": "https://clinicaltrials.gov/study/NCT03191383",
        "date": "2018-10-15"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-251154-vaccine-glaxosmithkline",
      "name": "Synflorix™",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Rotavirus",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2015-03-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01110044"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine",
          "nctId": "NCT01110044",
          "phase": "PHASE2",
          "population": "Infections, Rotavirus",
          "comparator": "",
          "expectedReadout": "2012-08",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2012-08 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01110044",
        "url": "https://clinicaltrials.gov/study/NCT01110044",
        "date": "2015-03-27"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rotavirus-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-gsk-biologicals-investigational-h1n1-influenza-vaccine-gsk234027",
      "name": "GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2015-03-23",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01008956"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults",
          "nctId": "NCT01008956",
          "phase": "PHASE2",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "2010-10",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2010-10 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01008956",
        "url": "https://clinicaltrials.gov/study/NCT01008956",
        "date": "2015-03-23"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-covid-19-vaccine-vero-cell-inactivated-medium-dose-sinovac-resea",
      "name": "COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)",
      "developer": "Sinovac Research and Development Co., Ltd.",
      "targetDisease": "COVID-19",
      "platform": "Inactivated",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2023-09-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05254236"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy ",
          "nctId": "NCT05254236",
          "phase": "PHASE2",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2022-03-10",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2022-03-10 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05254236",
        "url": "https://clinicaltrials.gov/study/NCT05254236",
        "date": "2023-09-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-sii-b-1-351-novavax",
      "name": "SII B.1.351",
      "developer": "Novavax",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2022-05-31",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05029856"
      ],
      "trialSubEntries": [
        {
          "trialName": "Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adul",
          "nctId": "NCT05029856",
          "phase": "PHASE1,PHASE2",
          "population": "Covid19",
          "comparator": "",
          "expectedReadout": "2022-08",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2022-08 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05029856",
        "url": "https://clinicaltrials.gov/study/NCT05029856",
        "date": "2022-05-31"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-medium-dose-covid-19-vaccine-vero-cell-inactivated-sinovac-resea",
      "name": "High-dose COVID-19 Vaccine(Vero Cell),Inactivated",
      "developer": "Sinovac Research and Development Co., Ltd.",
      "targetDisease": "COVID-19",
      "platform": "Inactivated",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2022-08-11",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05150496"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccin",
          "nctId": "NCT05150496",
          "phase": "PHASE2",
          "population": "COVID-19",
          "comparator": "",
          "expectedReadout": "2023-01-15",
          "status": "SUSPENDED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2023-01-15 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05150496",
        "url": "https://clinicaltrials.gov/study/NCT05150496",
        "date": "2022-08-11"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: SUSPENDED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-gsk-biologicals-investigational-tb-vaccine-gsk-692342-glaxosmith",
      "name": "GSK Biologicals' investigational TB vaccine GSK 692342",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Tuberculosis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2018-08-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01424501"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease",
          "nctId": "NCT01424501",
          "phase": "PHASE2",
          "population": "Tuberculosis",
          "comparator": "",
          "expectedReadout": "2014-04-01",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2014-04-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01424501",
        "url": "https://clinicaltrials.gov/study/NCT01424501",
        "date": "2018-08-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-immunotherapeutic-gsk2132231a-glaxosmithkline",
      "name": "Immunotherapeutic GSK2132231A",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Melanoma",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2017-07-12",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00849875"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients",
          "nctId": "NCT00849875",
          "phase": "PHASE2",
          "population": "Melanoma",
          "comparator": "",
          "expectedReadout": "2014-11-17",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2014-11-17 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00849875",
        "url": "https://clinicaltrials.gov/study/NCT00849875",
        "date": "2017-07-12"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-cmb305-immune-design-a-subsidiary-of-merck-co-inc-rahway-new-jer",
      "name": "CMB305",
      "developer": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "targetDisease": "Sarcoma",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2020-07-07",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02609984"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma ",
          "nctId": "NCT02609984",
          "phase": "PHASE2",
          "population": "Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma",
          "comparator": "",
          "expectedReadout": "2019-02-06",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2019-02-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02609984",
        "url": "https://clinicaltrials.gov/study/NCT02609984",
        "date": "2020-07-07"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-mrkad5-hiv-1-gag-pol-nef-4-x-10-9-ad5-vg-dose-v520-merck-sharp-d",
      "name": "MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "HIV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2015-08-25",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00350623"
      ],
      "trialSubEntries": [
        {
          "trialName": "Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)",
          "nctId": "NCT00350623",
          "phase": "PHASE2",
          "population": "HIV Infections",
          "comparator": "",
          "expectedReadout": "2008-05",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2008-05 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00350623",
        "url": "https://clinicaltrials.gov/study/NCT00350623",
        "date": "2015-08-25"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-acam1000-sanofi-pasteur-a-sanofi-company",
      "name": "ACAM1000",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Smallpox",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2014-01-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00053508"
      ],
      "trialSubEntries": [
        {
          "trialName": "Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination",
          "nctId": "NCT00053508",
          "phase": "PHASE2",
          "population": "Smallpox",
          "comparator": "",
          "expectedReadout": "2003-03",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2003-03 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00053508",
        "url": "https://clinicaltrials.gov/study/NCT00053508",
        "date": "2014-01-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-acc-001-qs21-3mcg-pfizer",
      "name": "ACC-001+ QS21 (3mcg)",
      "developer": "Pfizer",
      "targetDisease": "Alzheimer Disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2016-04-01",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00960531"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease",
          "nctId": "NCT00960531",
          "phase": "PHASE2",
          "population": "Alzheimer Disease",
          "comparator": "",
          "expectedReadout": "2013-12",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2013-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00960531",
        "url": "https://clinicaltrials.gov/study/NCT00960531",
        "date": "2016-04-01"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-alvac-2-melanoma-multi-antigen-therapeutic-vaccine-sanofi-pasteu",
      "name": "Intron A, Interferon alpha -2b",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Melanoma",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2016-04-14",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00613509"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma",
          "nctId": "NCT00613509",
          "phase": "PHASE2",
          "population": "Melanoma, Cancer",
          "comparator": "",
          "expectedReadout": "2010-04",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2010-04 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00613509",
        "url": "https://clinicaltrials.gov/study/NCT00613509",
        "date": "2016-04-14"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-staphylococcus-aureus-4-antigen-sa4ag-vaccine-pfizer",
      "name": "Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine",
      "developer": "Pfizer",
      "targetDisease": "Staphylococcal Vaccine",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2021-01-05",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02388165"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel I",
          "nctId": "NCT02388165",
          "phase": "PHASE2",
          "population": "Staphylococcal Vaccine",
          "comparator": "",
          "expectedReadout": "2019-06-26",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2019-06-26 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02388165",
        "url": "https://clinicaltrials.gov/study/NCT02388165",
        "date": "2021-01-05"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-acc-001-pfizer",
      "name": "ACC-001",
      "developer": "Pfizer",
      "targetDisease": "Alzheimer's Disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2014-12-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01238991"
      ],
      "trialSubEntries": [
        {
          "trialName": "Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild T",
          "nctId": "NCT01238991",
          "phase": "PHASE2",
          "population": "Alzheimer's Disease",
          "comparator": "",
          "expectedReadout": "2013-12",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2013-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01238991",
        "url": "https://clinicaltrials.gov/study/NCT01238991",
        "date": "2014-12-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-trivalent-mrkad5-hiv-1-gag-pol-nef-1-5x10-10-ad-vg-dose-merck-sh",
      "name": "Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "HIV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2015-10-06",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00095576"
      ],
      "trialSubEntries": [
        {
          "trialName": "Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)",
          "nctId": "NCT00095576",
          "phase": "PHASE2",
          "population": "AIDS, HIV Infections",
          "comparator": "",
          "expectedReadout": "2007-09",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2007-09 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00095576",
        "url": "https://clinicaltrials.gov/study/NCT00095576",
        "date": "2015-10-06"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-amb-a-1-immunostimulatory-oligodeoxyribonucleotide-conjugate-dyn",
      "name": "Histamine base",
      "developer": "Dynavax Technologies Corporation",
      "targetDisease": "Rhinitis, Allergic, Seasonal",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2019-04-16",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00387738"
      ],
      "trialSubEntries": [
        {
          "trialName": "Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults",
          "nctId": "NCT00387738",
          "phase": "PHASE2",
          "population": "Rhinitis, Allergic, Seasonal",
          "comparator": "",
          "expectedReadout": "2007-05",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2007-05 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00387738",
        "url": "https://clinicaltrials.gov/study/NCT00387738",
        "date": "2019-04-16"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-purified-inactivated-zika-virus-vaccine-pizv-takeda",
      "name": "Purified Inactivated Zika Virus Vaccine (PIZV)",
      "developer": "Takeda",
      "targetDisease": "Healthy Volunteers",
      "platform": "Inactivated",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2024-03-13",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05469802"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults",
          "nctId": "NCT05469802",
          "phase": "PHASE2",
          "population": "Healthy Volunteers",
          "comparator": "",
          "expectedReadout": "2024-07-05",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2024-07-05 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05469802",
        "url": "https://clinicaltrials.gov/study/NCT05469802",
        "date": "2024-03-13"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-400-u-ev71-vaccine-with-adjuvant-sinovac-biotech-co-ltd",
      "name": "400 U EV71 vaccine with adjuvant",
      "developer": "Sinovac Biotech Co., Ltd",
      "targetDisease": "Infection, Viral, Enterovirus",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2021-07-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01812135"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants",
          "nctId": "NCT01812135",
          "phase": "PHASE2",
          "population": "Infection, Viral, Enterovirus",
          "comparator": "",
          "expectedReadout": "2011-11",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2011-11 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01812135",
        "url": "https://clinicaltrials.gov/study/NCT01812135",
        "date": "2021-07-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_2"
    },
    {
      "candidateId": "ctgov-pn-maps30plus-glaxosmithkline",
      "name": "Pn-MAPS30plus",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Pneumococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-02-12",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07406334",
        "NCT07406347",
        "NCT07428759"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months",
          "nctId": "NCT07406334",
          "phase": "PHASE1",
          "population": "Pneumonia, Bacterial",
          "comparator": "",
          "expectedReadout": "2027-02-22",
          "status": "NOT_YET_RECRUITING"
        },
        {
          "trialName": "A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose",
          "nctId": "NCT07406347",
          "phase": "PHASE1",
          "population": "Pneumonia, Bacterial",
          "comparator": "",
          "expectedReadout": "2028-04-03",
          "status": "NOT_YET_RECRUITING"
        },
        {
          "trialName": "Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years",
          "nctId": "NCT07428759",
          "phase": "PHASE1",
          "population": "Pneumonia, Bacterial",
          "comparator": "",
          "expectedReadout": "2026-12-09",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-02-22 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07406334",
        "url": "https://clinicaltrials.gov/study/NCT07406334",
        "date": "2026-02-12"
      },
      "additionalCitations": [
        {
          "label": "NCT07406347 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07406347",
          "date": "2026-07-10"
        },
        {
          "label": "NCT07428759 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07428759",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 3 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-investigational-mrna-seasonal-flu-covid-19-combination-flu-covm-",
      "name": "Licensed Seasonal Influenza Vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "COVID-19",
      "platform": "mRNA",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-06-30",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07464314"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults",
          "nctId": "NCT07464314",
          "phase": "PHASE1",
          "population": "Influenza, Human+COVID-19",
          "comparator": "",
          "expectedReadout": "2026-12-03",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-12-03 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07464314",
        "url": "https://clinicaltrials.gov/study/NCT07464314",
        "date": "2026-06-30"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-v118c-stage-1-merck-sharp-dohme-llc",
      "name": "V118C (Stage 1)",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Pneumococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-04-17",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07300267"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)",
          "nctId": "NCT07300267",
          "phase": "PHASE1",
          "population": "Pneumococcal Infection",
          "comparator": "",
          "expectedReadout": "2028-10-24",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-10-24 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07300267",
        "url": "https://clinicaltrials.gov/study/NCT07300267",
        "date": "2026-04-17"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-h5-flu-investigational-medical-product-imp-1-sanofi",
      "name": "H5 Flu IMP 2",
      "developer": "Sanofi",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-05-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07516418"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18",
          "nctId": "NCT07516418",
          "phase": "PHASE1",
          "population": "Respiratory Syncytial Virus (RSV), Influenza A(H5N1)",
          "comparator": "",
          "expectedReadout": "2027-04-04",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-04-04 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07516418",
        "url": "https://clinicaltrials.gov/study/NCT07516418",
        "date": "2026-05-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-adsorbed-acellular-pertussis-3-component-diphtheria-tetanus-pert",
      "name": "DTcP-Hib-MCV4",
      "developer": "CanSino Biologics Inc.",
      "targetDisease": "Influenza",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2025-12-31",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07203755"
      ],
      "trialSubEntries": [
        {
          "trialName": "Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135",
          "nctId": "NCT07203755",
          "phase": "PHASE1",
          "population": "Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection",
          "comparator": "",
          "expectedReadout": "2029-02",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2029-02 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07203755",
        "url": "https://clinicaltrials.gov/study/NCT07203755",
        "date": "2025-12-31"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-low-dose-rsv-mrna-vaccine-sinovac-biotech-co-ltd",
      "name": "Low-dose RSV mRNA vaccine",
      "developer": "Sinovac Biotech Co., Ltd",
      "targetDisease": "RSV",
      "platform": "mRNA",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-02-18",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07418229"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine",
          "nctId": "NCT07418229",
          "phase": "PHASE1",
          "population": "RSV, mRNA Vaccine",
          "comparator": "",
          "expectedReadout": "2026-06-30",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-06-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07418229",
        "url": "https://clinicaltrials.gov/study/NCT07418229",
        "date": "2026-02-18"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-high-dose-group-acyw135x-meningococcal-conjugate-vaccine-sinovac",
      "name": "low-dose Group ACYW135X Meningococcal Conjugate Vaccine",
      "developer": "Sinovac Life Sciences Co., Ltd.",
      "targetDisease": "Meningococcal disease",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-01-28",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07374510"
      ],
      "trialSubEntries": [
        {
          "trialName": "Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine",
          "nctId": "NCT07374510",
          "phase": "PHASE1",
          "population": "Meningococcal Meningitis",
          "comparator": "",
          "expectedReadout": "2026-09-10",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-09-10 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07374510",
        "url": "https://clinicaltrials.gov/study/NCT07374510",
        "date": "2026-01-28"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-recombinant-poliomyelitis-vaccine-rpv-serum-institute-of-india-p",
      "name": "Recombinant Poliomyelitis Vaccine (rPV)",
      "developer": "Serum Institute of India Pvt. Ltd.",
      "targetDisease": "Polio",
      "platform": "Protein / subunit",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-07-10",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07688369"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults",
          "nctId": "NCT07688369",
          "phase": "PHASE1",
          "population": "Polio Immunity",
          "comparator": "",
          "expectedReadout": "2026-11",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-11 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07688369",
        "url": "https://clinicaltrials.gov/study/NCT07688369",
        "date": "2026-07-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "polio-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-lyophilized-haemophilus-influenzae-type-b-conjugate-vaccine-cans",
      "name": "Haemophilus Influenzae Type b Conjugate Vaccine",
      "developer": "CanSino Biologics Inc.",
      "targetDisease": "Influenza",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2025-07-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06621654"
      ],
      "trialSubEntries": [
        {
          "trialName": "Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine",
          "nctId": "NCT06621654",
          "phase": "PHASE1",
          "population": "Haemophilus Influenzae Type B Infection",
          "comparator": "",
          "expectedReadout": "2026-10",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-10 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06621654",
        "url": "https://clinicaltrials.gov/study/NCT06621654",
        "date": "2025-07-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-trivalent-rsv-hmpv-piv3-vaccine-candidate-sanofi",
      "name": "bivalent (RSV/hMPV) unlicensed comparator",
      "developer": "Sanofi",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-05-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07295028"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults",
          "nctId": "NCT07295028",
          "phase": "PHASE1",
          "population": "Lower Respiratory Tract Disease, Healthy Participants",
          "comparator": "",
          "expectedReadout": "2026-04-21",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-04-21 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07295028",
        "url": "https://clinicaltrials.gov/study/NCT07295028",
        "date": "2026-05-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pg4-vaccine-in-buffer-1-with-low-dose-pa-001-pfizer",
      "name": "PG4 in Buffer 1 with low dose PA-002",
      "developer": "Pfizer",
      "targetDisease": "Pneumococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-06-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07086677"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Learn About How a New Pneumococcal Vaccine Works in Adults",
          "nctId": "NCT07086677",
          "phase": "PHASE1",
          "population": "Streptococcus Pneumoniae",
          "comparator": "",
          "expectedReadout": "2027-10-21",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-10-21 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07086677",
        "url": "https://clinicaltrials.gov/study/NCT07086677",
        "date": "2026-06-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-vxb-241-60-mcg-low-dose-sanofi",
      "name": "VXB-241 240 mcg",
      "developer": "Sanofi",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-05-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06556147"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults",
          "nctId": "NCT06556147",
          "phase": "PHASE1",
          "population": "Healthy Volunteers",
          "comparator": "",
          "expectedReadout": "2025-02-14",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-02-14 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06556147",
        "url": "https://clinicaltrials.gov/study/NCT06556147",
        "date": "2026-05-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-covid-19-therapeutic-biologic-mix-novavax-covid-19-vaccine-plus-",
      "name": "COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use",
      "developer": "Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-06-10",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03305341"
      ],
      "trialSubEntries": [
        {
          "trialName": "Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix",
          "nctId": "NCT03305341",
          "phase": "EARLY_PHASE1",
          "population": "Covid19",
          "comparator": "",
          "expectedReadout": "2026-11-18",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-11-18 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03305341",
        "url": "https://clinicaltrials.gov/study/NCT03305341",
        "date": "2026-06-10"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-investigational-rsv-vaccine-1-glaxosmithkline",
      "name": "Investigational RSV vaccine 1",
      "developer": "GlaxoSmithKline",
      "targetDisease": "RSV",
      "platform": "mRNA",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2025-09-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06573281"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Year",
          "nctId": "NCT06573281",
          "phase": "PHASE1",
          "population": "Respiratory Syncytial Virus Infections",
          "comparator": "",
          "expectedReadout": "2026-04-13",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-04-13 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06573281",
        "url": "https://clinicaltrials.gov/study/NCT06573281",
        "date": "2025-09-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-20vpnc-pfizer",
      "name": "20vPnC",
      "developer": "Pfizer",
      "targetDisease": "Pneumococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-03-12",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07023081"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant",
          "nctId": "NCT07023081",
          "phase": "PHASE1",
          "population": "Pneumococcal Disease",
          "comparator": "",
          "expectedReadout": "2027-05-14",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-05-14 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07023081",
        "url": "https://clinicaltrials.gov/study/NCT07023081",
        "date": "2026-03-12"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-low-dose-strep-a-alum-glaxosmithkline",
      "name": "Low dose Strep A Alum",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Streptococcal Infections",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2025-08-11",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07085702"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydr",
          "nctId": "NCT07085702",
          "phase": "PHASE1",
          "population": "Streptococcal Infections",
          "comparator": "",
          "expectedReadout": "2026-11-30",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-11-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07085702",
        "url": "https://clinicaltrials.gov/study/NCT07085702",
        "date": "2025-08-11"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-v350a-merck-sharp-dohme-llc",
      "name": "V350A",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Healthy",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-06-01",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06655324"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).",
          "nctId": "NCT06655324",
          "phase": "PHASE1",
          "population": "Healthy",
          "comparator": "",
          "expectedReadout": "2028-07-17",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-07-17 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06655324",
        "url": "https://clinicaltrials.gov/study/NCT06655324",
        "date": "2026-06-01"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-placebo-vaxcyte-inc",
      "name": "VAX-A1 Low",
      "developer": "Vaxcyte, Inc.",
      "targetDisease": "Group A Streptococcal Infection",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-06-16",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07616934"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults",
          "nctId": "NCT07616934",
          "phase": "PHASE1",
          "population": "Group A Streptococcal Infection",
          "comparator": "",
          "expectedReadout": "2027-12",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07616934",
        "url": "https://clinicaltrials.gov/study/NCT07616934",
        "date": "2026-06-16"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-durvalumab-astrazeneca",
      "name": "Durvalumab",
      "developer": "AstraZeneca",
      "targetDisease": "Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-04-13",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04686305"
      ],
      "trialSubEntries": [
        {
          "trialName": "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H",
          "nctId": "NCT04686305",
          "phase": "PHASE1",
          "population": "Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
          "comparator": "",
          "expectedReadout": "2027-06-30",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-06-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04686305",
        "url": "https://clinicaltrials.gov/study/NCT04686305",
        "date": "2026-04-13"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-v118e-merck-sharp-dohme-llc",
      "name": "V118E",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Healthy",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-06-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07168915"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of V118E in Healthy Participants (V118E-003)",
          "nctId": "NCT07168915",
          "phase": "PHASE1",
          "population": "Healthy",
          "comparator": "",
          "expectedReadout": "2027-11-12",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-11-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07168915",
        "url": "https://clinicaltrials.gov/study/NCT07168915",
        "date": "2026-06-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-bnt116-biontech-se",
      "name": "BNT116",
      "developer": "BioNTech SE",
      "targetDisease": "Non-Small Cell Lung Cancer",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-04-14",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05142189"
      ],
      "trialSubEntries": [
        {
          "trialName": "Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patie",
          "nctId": "NCT05142189",
          "phase": "PHASE1",
          "population": "Non-Small Cell Lung Cancer",
          "comparator": "",
          "expectedReadout": "2030-02",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2030-02 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05142189",
        "url": "https://clinicaltrials.gov/study/NCT05142189",
        "date": "2026-04-14"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pan-salmonella-with-alum-low-dose-vaccine-glaxosmithkline",
      "name": "Typhoid Vi conjugate vaccine",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Salmonella Infections",
      "platform": "Conjugate vaccine",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-06-23",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07663032"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVG",
          "nctId": "NCT07663032",
          "phase": "PHASE1",
          "population": "Salmonella Infections",
          "comparator": "",
          "expectedReadout": "2027-11-14",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-11-14 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07663032",
        "url": "https://clinicaltrials.gov/study/NCT07663032",
        "date": "2026-06-23"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-v540d-merck-sharp-dohme-llc",
      "name": "V540D",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Healthy",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-03-13",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06688058"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)",
          "nctId": "NCT06688058",
          "phase": "PHASE1",
          "population": "Healthy",
          "comparator": "",
          "expectedReadout": "2026-11-30",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-11-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06688058",
        "url": "https://clinicaltrials.gov/study/NCT06688058",
        "date": "2026-03-13"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-bnt163-biontech-se",
      "name": "BNT163",
      "developer": "BioNTech SE",
      "targetDisease": "Genital Herpes Simplex Type 2",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2025-10-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05432583"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, a",
          "nctId": "NCT05432583",
          "phase": "PHASE1",
          "population": "Genital Herpes Simplex Type 2",
          "comparator": "",
          "expectedReadout": "2026-10",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-10 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05432583",
        "url": "https://clinicaltrials.gov/study/NCT05432583",
        "date": "2025-10-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mrna-1195-1-modernatx-inc",
      "name": "mRNA-1195.1",
      "developer": "ModernaTX, Inc.",
      "targetDisease": "EBV",
      "platform": "mRNA",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2025-09-30",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05831111"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants",
          "nctId": "NCT05831111",
          "phase": "PHASE1",
          "population": "Epstein-Barr Virus Infection",
          "comparator": "",
          "expectedReadout": "2026-10-07",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-10-07 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05831111",
        "url": "https://clinicaltrials.gov/study/NCT05831111",
        "date": "2025-09-30"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-cldn6-car-t-biontech-cell-gene-therapies-gmbh",
      "name": "CLDN6 CAR-T",
      "developer": "BioNTech Cell & Gene Therapies GmbH",
      "targetDisease": "Solid Tumor",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-06-18",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04503278"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigat",
          "nctId": "NCT04503278",
          "phase": "PHASE1",
          "population": "Solid Tumor",
          "comparator": "",
          "expectedReadout": "2028-08",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-08 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04503278",
        "url": "https://clinicaltrials.gov/study/NCT04503278",
        "date": "2026-06-18"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-gardasil-9-g9-merck-sharp-dohme-llc",
      "name": "V540B",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Healthy",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2025-08-03",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06623409"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).",
          "nctId": "NCT06623409",
          "phase": "PHASE1",
          "population": "Healthy",
          "comparator": "",
          "expectedReadout": "2026-11-20",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-11-20 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06623409",
        "url": "https://clinicaltrials.gov/study/NCT06623409",
        "date": "2025-08-03"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-fluzone-hd-influenza-vaccine-cidara-therapeutics-inc-a-subsidiar",
      "name": "Fluzone HD influenza vaccine",
      "developer": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "targetDisease": "Healthy Participants",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_1",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_1",
          "date": "2026-03-24",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07300085"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine",
          "nctId": "NCT07300085",
          "phase": "PHASE1",
          "population": "Healthy Participants",
          "comparator": "",
          "expectedReadout": "2026-12",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07300085",
        "url": "https://clinicaltrials.gov/study/NCT07300085",
        "date": "2026-03-24"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-mva-smallpox-vaccine-sanofi-pasteur-a-sanofi-company",
      "name": "MVA Smallpox Vaccine",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "HIV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2014-01-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00282581",
        "NCT00389103"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive",
          "nctId": "NCT00282581",
          "phase": "PHASE1",
          "population": "HIV Infections, Smallpox",
          "comparator": "",
          "expectedReadout": "2007-07",
          "status": "TERMINATED"
        },
        {
          "trialName": "Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)",
          "nctId": "NCT00389103",
          "phase": "PHASE1",
          "population": "Smallpox, Atopic Dermatitis",
          "comparator": "",
          "expectedReadout": "2007-01",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2007-07 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00282581",
        "url": "https://clinicaltrials.gov/study/NCT00282581",
        "date": "2014-01-22"
      },
      "additionalCitations": [
        {
          "label": "NCT00389103 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT00389103",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED, WITHDRAWN",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-v590-merck-sharp-dohme-llc",
      "name": "V590",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "COVID-19",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2021-12-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04569786"
      ],
      "trialSubEntries": [
        {
          "trialName": "Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)",
          "nctId": "NCT04569786",
          "phase": "PHASE1",
          "population": "Coronavirus Disease (COVID-19)",
          "comparator": "",
          "expectedReadout": "2021-02-18",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2021-02-18 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04569786",
        "url": "https://clinicaltrials.gov/study/NCT04569786",
        "date": "2021-12-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "covid-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-comparator-rotateq-merck-sharp-dohme-llc",
      "name": "Comparator: RotaTeq",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Rotavirus",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2015-05-01",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00836498"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)",
          "nctId": "NCT00836498",
          "phase": "PHASE1",
          "population": "Rotavirus",
          "comparator": "",
          "expectedReadout": "2010-01",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2010-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00836498",
        "url": "https://clinicaltrials.gov/study/NCT00836498",
        "date": "2015-05-01"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rotavirus-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-gsk2231395a-glaxosmithkline",
      "name": "GSK2231395A",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2017-10-31",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00849069"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine",
          "nctId": "NCT00849069",
          "phase": "PHASE1",
          "population": "Haemophilus Influenzae, Streptococcus Pneumoniae",
          "comparator": "",
          "expectedReadout": "2009-04-07",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2009-04-07 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00849069",
        "url": "https://clinicaltrials.gov/study/NCT00849069",
        "date": "2017-10-31"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-investigational-h7n9-vaccine-gsk3277510a-glaxosmithkline",
      "name": "Investigational H7N9 vaccine GSK3277510A",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2016-06-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02177734"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A i",
          "nctId": "NCT02177734",
          "phase": "PHASE1",
          "population": "Influenza",
          "comparator": "",
          "expectedReadout": "2016-06",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2016-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02177734",
        "url": "https://clinicaltrials.gov/study/NCT02177734",
        "date": "2016-06-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-ixiaro-valneva-austria-gmbh",
      "name": "IXIARO",
      "developer": "Valneva Austria GmbH",
      "targetDisease": "Japanese encephalitis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2013-03-08",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01559831"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination",
          "nctId": "NCT01559831",
          "phase": "PHASE1",
          "population": "Japanese Encephalitis",
          "comparator": "",
          "expectedReadout": "2012-12",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2012-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01559831",
        "url": "https://clinicaltrials.gov/study/NCT01559831",
        "date": "2013-03-08"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "japanese-encephalitis-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-mva-bn-rsv-bavarian-nordic",
      "name": "MVA-BN-RSV",
      "developer": "Bavarian Nordic",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2018-08-27",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02864628"
      ],
      "trialSubEntries": [
        {
          "trialName": "RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.",
          "nctId": "NCT02864628",
          "phase": "PHASE1",
          "population": "Respiratory Syncytial Virus Infections",
          "comparator": "",
          "expectedReadout": "2017-10-27",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2017-10-27 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02864628",
        "url": "https://clinicaltrials.gov/study/NCT02864628",
        "date": "2018-08-27"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-cv9202-curevac",
      "name": "CV9202",
      "developer": "CureVac",
      "targetDisease": "Non-Small Cell Lung Carcinoma",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2016-08-05",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT01915524"
      ],
      "trialSubEntries": [
        {
          "trialName": "Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)",
          "nctId": "NCT01915524",
          "phase": "PHASE1",
          "population": "Non-Small Cell Lung Carcinoma",
          "comparator": "",
          "expectedReadout": "2016-07",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2016-07 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT01915524",
        "url": "https://clinicaltrials.gov/study/NCT01915524",
        "date": "2016-08-05"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-v941-merck-sharp-dohme-llc",
      "name": "V941",
      "developer": "Merck Sharp & Dohme LLC",
      "targetDisease": "Neoplasms",
      "platform": "mRNA",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-01-28",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03948763"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)",
          "nctId": "NCT03948763",
          "phase": "PHASE1",
          "population": "Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms",
          "comparator": "",
          "expectedReadout": "2022-08-25",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2022-08-25 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03948763",
        "url": "https://clinicaltrials.gov/study/NCT03948763",
        "date": "2025-01-28"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-neo-pv-01-biontech-us-inc",
      "name": "APX005M",
      "developer": "BioNTech US Inc.",
      "targetDisease": "Metastatic Melanoma",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2020-09-03",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03597282"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma",
          "nctId": "NCT03597282",
          "phase": "PHASE1",
          "population": "Metastatic Melanoma",
          "comparator": "",
          "expectedReadout": "2020-05-05",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2020-05-05 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03597282",
        "url": "https://clinicaltrials.gov/study/NCT03597282",
        "date": "2020-09-03"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-ad4-mgag-emergent-biosolutions",
      "name": "Ad4-mgag",
      "developer": "Emergent BioSolutions",
      "targetDisease": "HIV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2024-03-18",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02771730"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults",
          "nctId": "NCT02771730",
          "phase": "PHASE1",
          "population": "Healthy Volunteer, HIV Vaccine",
          "comparator": "",
          "expectedReadout": "2017-02",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2017-02 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02771730",
        "url": "https://clinicaltrials.gov/study/NCT02771730",
        "date": "2024-03-18"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-jnj-64041757-cohort-1a-and-1b-janssen-research-development-llc",
      "name": "JNJ-64041757 (Cohort 1A and 1B)",
      "developer": "Janssen Research & Development, LLC",
      "targetDisease": "Carcinoma, Non-Small-Cell Lung",
      "platform": "Live attenuated",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2025-02-03",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02592967"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Sma",
          "nctId": "NCT02592967",
          "phase": "PHASE1",
          "population": "Carcinoma, Non-Small-Cell Lung",
          "comparator": "",
          "expectedReadout": "2018-08-14",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2018-08-14 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02592967",
        "url": "https://clinicaltrials.gov/study/NCT02592967",
        "date": "2025-02-03"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-hiv-1-gag-dna-formulated-with-bupivacaine-wyeth-is-now-a-wholly-",
      "name": "IL-15 DNA (formulated with bupivacaine)",
      "developer": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "targetDisease": "HIV",
      "platform": "DNA",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2007-12-05",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00195312"
      ],
      "trialSubEntries": [
        {
          "trialName": "Study Evaluating Vaccine in Adults With HIV",
          "nctId": "NCT00195312",
          "phase": "PHASE1",
          "population": "HIV Infections",
          "comparator": "",
          "expectedReadout": "TBD",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "See linked ClinicalTrials.gov records for primary completion dates",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00195312",
        "url": "https://clinicaltrials.gov/study/NCT00195312",
        "date": "2007-12-05"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-vaccine-diluent-buffer-sanofi",
      "name": "Vaccine diluent buffer",
      "developer": "Sanofi",
      "targetDisease": "Clostridium Difficile Infection",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2012-05-21",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT00772954"
      ],
      "trialSubEntries": [
        {
          "trialName": "Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity",
          "nctId": "NCT00772954",
          "phase": "PHASE1",
          "population": "Clostridium Difficile Infection, Clostridium Difficile Diarrhea",
          "comparator": "",
          "expectedReadout": "2006-06",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2006-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT00772954",
        "url": "https://clinicaltrials.gov/study/NCT00772954",
        "date": "2012-05-21"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-hsv-2-formulation-1-sanofi-pasteur-a-sanofi-company",
      "name": "HSV 2 Formulation 1",
      "developer": "Sanofi Pasteur, a Sanofi Company",
      "targetDisease": "Genital Herpes",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2022-10-25",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04222985"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2",
          "nctId": "NCT04222985",
          "phase": "PHASE1",
          "population": "Genital Herpes",
          "comparator": "",
          "expectedReadout": "2021-05-19",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2021-05-19 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04222985",
        "url": "https://clinicaltrials.gov/study/NCT04222985",
        "date": "2022-10-25"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-pf-06755992-pfizer",
      "name": "PF-06755992",
      "developer": "Pfizer",
      "targetDisease": "Prostatic Neoplasms",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2023-11-02",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT02616185"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)",
          "nctId": "NCT02616185",
          "phase": "PHASE1",
          "population": "Prostatic Neoplasms",
          "comparator": "",
          "expectedReadout": "2021-02-23",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2021-02-23 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT02616185",
        "url": "https://clinicaltrials.gov/study/NCT02616185",
        "date": "2023-11-02"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-pxvx0047-vaccine-emergent-biosolutions",
      "name": "PXVX0047 Vaccine",
      "developer": "Emergent BioSolutions",
      "targetDisease": "Adenoviral Infection",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2024-03-18",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03160339"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047",
          "nctId": "NCT03160339",
          "phase": "PHASE1",
          "population": "Adenoviral Infection",
          "comparator": "",
          "expectedReadout": "2017-11-27",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2017-11-27 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03160339",
        "url": "https://clinicaltrials.gov/study/NCT03160339",
        "date": "2024-03-18"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-lower-dose-formulation-of-hsv-vaccine-gsk4108771a-glaxosmithklin",
      "name": "Lower dose formulation of HSV vaccine (GSK4108771A)",
      "developer": "GlaxoSmithKline",
      "targetDisease": "Herpes Simplex",
      "platform": "Biological (unspecified platform)",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2021-06-28",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04762511"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy P",
          "nctId": "NCT04762511",
          "phase": "PHASE1",
          "population": "Herpes Simplex",
          "comparator": "",
          "expectedReadout": "2021-05-26",
          "status": "TERMINATED"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2021-05-26 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04762511",
        "url": "https://clinicaltrials.gov/study/NCT04762511",
        "date": "2021-06-28"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: TERMINATED",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-cv09070101-mrna-vaccine-cvhnlc-50-g-curevac",
      "name": "CV09070101 mRNA vaccine (CVHNLC) 50 µg",
      "developer": "CureVac",
      "targetDisease": "Squamous NSCLC",
      "platform": "mRNA",
      "currentStage": "discontinued",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "discontinued",
          "date": "2026-05-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07073183"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)",
          "nctId": "NCT07073183",
          "phase": "PHASE1",
          "population": "Squamous NSCLC",
          "comparator": "",
          "expectedReadout": "2029-12-31",
          "status": "WITHDRAWN"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2029-12-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07073183",
        "url": "https://clinicaltrials.gov/study/NCT07073183",
        "date": "2026-05-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.",
      "discontinuedReason": "Registry status: WITHDRAWN",
      "stageAtDiscontinuation": "phase_1"
    },
    {
      "candidateId": "ctgov-gardasil-9-emory-university",
      "name": "Gardasil-9",
      "developer": "Emory University",
      "targetDisease": "HPV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-08-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06799494",
        "NCT05031078"
      ],
      "trialSubEntries": [
        {
          "trialName": "HPV Vaccine Reduced Dose",
          "nctId": "NCT06799494",
          "phase": "PHASE4",
          "population": "HPV",
          "comparator": "",
          "expectedReadout": "2028-09",
          "status": "RECRUITING"
        },
        {
          "trialName": "Assessing Durable Antibody Response to HPV Vaccination",
          "nctId": "NCT05031078",
          "phase": "PHASE4",
          "population": "HPV",
          "comparator": "",
          "expectedReadout": "2024-10-23",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-09 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06799494",
        "url": "https://clinicaltrials.gov/study/NCT06799494",
        "date": "2025-08-20"
      },
      "additionalCitations": [
        {
          "label": "NCT05031078 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05031078",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-influenza-vaccination-wroclaw-medical-university",
      "name": "Influenza vaccination",
      "developer": "Wroclaw Medical University",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-07-23",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06725927",
        "NCT07617376"
      ],
      "trialSubEntries": [
        {
          "trialName": "Vaccination Against Influenza Pre-discharge in Heart Failure",
          "nctId": "NCT06725927",
          "phase": "PHASE4",
          "population": "Heart Failure",
          "comparator": "",
          "expectedReadout": "2025-11-30",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions",
          "nctId": "NCT07617376",
          "phase": "PHASE4",
          "population": "Myocardial Infarction, Decompensated Chronic Heart Failure, Acute Heart Failure (AHF)",
          "comparator": "",
          "expectedReadout": "2026-12-31",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-11-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06725927",
        "url": "https://clinicaltrials.gov/study/NCT06725927",
        "date": "2025-07-23"
      },
      "additionalCitations": [
        {
          "label": "NCT07617376 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07617376",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-bcg-vaccine-bandim-health-project",
      "name": "BCG vaccine",
      "developer": "Bandim Health Project",
      "targetDisease": "Measles / Mumps / Rubella",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2024-01-19",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04899765",
        "NCT07005726"
      ],
      "trialSubEntries": [
        {
          "trialName": "Measles and BCG Vaccines for Mother and Child",
          "nctId": "NCT04899765",
          "phase": "PHASE4",
          "population": "Vaccine Preventable Disease, Measles, Mother-Infant Interaction",
          "comparator": "",
          "expectedReadout": "2025-12-31",
          "status": "RECRUITING"
        },
        {
          "trialName": "BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa",
          "nctId": "NCT07005726",
          "phase": "PHASE4",
          "population": "Infant Morbidity, Infant Mortality, Non-Specific Effects of Vaccines",
          "comparator": "",
          "expectedReadout": "2030-05",
          "status": "ENROLLING_BY_INVITATION"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-12-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04899765",
        "url": "https://clinicaltrials.gov/study/NCT04899765",
        "date": "2024-01-19"
      },
      "additionalCitations": [
        {
          "label": "NCT07005726 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07005726",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "mmr-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-hpv-vaccine-university-of-washington",
      "name": "HPV vaccine",
      "developer": "University of Washington",
      "targetDisease": "HPV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-05",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04235257",
        "NCT05291871"
      ],
      "trialSubEntries": [
        {
          "trialName": "Intradermal, Fractional Dose of HPV Vaccines:",
          "nctId": "NCT04235257",
          "phase": "PHASE4",
          "population": "HPV Infection, HPV Vaccine",
          "comparator": "",
          "expectedReadout": "2026-12-31",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Immunogenicity of Fractional Dose of the HPV Vaccines",
          "nctId": "NCT05291871",
          "phase": "PHASE4",
          "population": "HPV Infection, HPV Vaccine",
          "comparator": "",
          "expectedReadout": "2026-12-31",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-12-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04235257",
        "url": "https://clinicaltrials.gov/study/NCT04235257",
        "date": "2026-05-05"
      },
      "additionalCitations": [
        {
          "label": "NCT05291871 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05291871",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-diphtheria-toxoid-tetanus-toxoid-acellular-pertussis-vaccine-ads",
      "name": "Recombinant Human Papillomavirus Bivalent Vaccine",
      "developer": "National Cancer Institute (NCI)",
      "targetDisease": "HPV",
      "platform": "Protein / subunit",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-09-04",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03180034",
        "NCT05237947"
      ],
      "trialSubEntries": [
        {
          "trialName": "Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESC",
          "nctId": "NCT03180034",
          "phase": "PHASE4",
          "population": "Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma",
          "comparator": "",
          "expectedReadout": "2025-08-21",
          "status": "ACTIVE_NOT_RECRUITING"
        },
        {
          "trialName": "Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO",
          "nctId": "NCT05237947",
          "phase": "PHASE4",
          "population": "Human Papillomavirus-Related Cervical Carcinoma",
          "comparator": "",
          "expectedReadout": "2026-08-31",
          "status": "ACTIVE_NOT_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-08-21 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03180034",
        "url": "https://clinicaltrials.gov/study/NCT03180034",
        "date": "2025-09-04"
      },
      "additionalCitations": [
        {
          "label": "NCT05237947 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05237947",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pneumococcal-vaccine-university-of-sao-paulo-general-hospital",
      "name": "Pneumococcal Vaccine",
      "developer": "University of Sao Paulo General Hospital",
      "targetDisease": "Autoimmune Rheumatologic Disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-03-04",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07252791",
        "NCT07242092"
      ],
      "trialSubEntries": [
        {
          "trialName": "Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases",
          "nctId": "NCT07252791",
          "phase": "PHASE4",
          "population": "Autoimmune Rheumatologic Disease",
          "comparator": "",
          "expectedReadout": "2026-12-30",
          "status": "RECRUITING"
        },
        {
          "trialName": "Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs",
          "nctId": "NCT07242092",
          "phase": "PHASE4",
          "population": "Autoimmune Rheumatic Diseases",
          "comparator": "",
          "expectedReadout": "2027-12-30",
          "status": "NOT_YET_RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-12-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07252791",
        "url": "https://clinicaltrials.gov/study/NCT07252791",
        "date": "2026-03-04"
      },
      "additionalCitations": [
        {
          "label": "NCT07242092 on ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT07242092",
          "date": "2026-07-10"
        }
      ],
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": null,
      "note": "Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pertagen-vaccine-mahidol-university",
      "name": "Adacel® vaccine",
      "developer": "Mahidol University",
      "targetDisease": "Diphtheria / Tetanus / Pertussis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-06-11",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06803524"
      ],
      "trialSubEntries": [
        {
          "trialName": "10-year Follow-up After a Single Dose Acellular Pertussis Vaccination",
          "nctId": "NCT06803524",
          "phase": "PHASE4",
          "population": "Pertussis",
          "comparator": "",
          "expectedReadout": "2026-03",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-03 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06803524",
        "url": "https://clinicaltrials.gov/study/NCT06803524",
        "date": "2025-06-11"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "dtap-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-hpv-nonavalent-vaccine-gardasil-9-canadian-immunization-research",
      "name": "HPV nonavalent vaccine (Gardasil-9)",
      "developer": "Canadian Immunization Research Network",
      "targetDisease": "HPV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-09-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07156084"
      ],
      "trialSubEntries": [
        {
          "trialName": "Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students",
          "nctId": "NCT07156084",
          "phase": "PHASE4",
          "population": "HPV Vaccine",
          "comparator": "",
          "expectedReadout": "2026-02",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-02 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07156084",
        "url": "https://clinicaltrials.gov/study/NCT07156084",
        "date": "2025-09-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-recombinant-herpes-zoster-vaccine-shingrix-tor-biering-s-rensen",
      "name": "Recombinant Herpes Zoster Vaccine (Shingrix)",
      "developer": "Tor Biering-Sørensen",
      "targetDisease": "Varicella / Zoster",
      "platform": "Protein / subunit",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-04",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07485283"
      ],
      "trialSubEntries": [
        {
          "trialName": "Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia",
          "nctId": "NCT07485283",
          "phase": "PHASE4",
          "population": "Cardiovascular Disease, Dementia",
          "comparator": "",
          "expectedReadout": "2029-04",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2029-04 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07485283",
        "url": "https://clinicaltrials.gov/study/NCT07485283",
        "date": "2026-05-04"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-human-papillomavirus-9-valent-vaccine-recombinant-louisiana-stat",
      "name": "human papillomavirus vaccine, recombinant",
      "developer": "Louisiana State University Health Sciences Center in New Orleans",
      "targetDisease": "HPV",
      "platform": "Protein / subunit",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-04-18",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05266898"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV",
          "nctId": "NCT05266898",
          "phase": "PHASE4",
          "population": "Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection",
          "comparator": "",
          "expectedReadout": "2025-12",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05266898",
        "url": "https://clinicaltrials.gov/study/NCT05266898",
        "date": "2025-04-18"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-prevenar-13-pneumovax-23-poitiers-university-hospital",
      "name": "PREVENAR20",
      "developer": "Poitiers University Hospital",
      "targetDisease": "Pneumococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-05-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04460235"
      ],
      "trialSubEntries": [
        {
          "trialName": "Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20)",
          "nctId": "NCT04460235",
          "phase": "PHASE4",
          "population": "Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin",
          "comparator": "",
          "expectedReadout": "2028-06",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-06 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04460235",
        "url": "https://clinicaltrials.gov/study/NCT04460235",
        "date": "2026-05-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-nonavalent-hpv-vaccine-9vhpv-gardasil-9-miquel-angel-pavon-ribas",
      "name": "Nonavalent HPV vaccine (9vHPV/Gardasil-9™).",
      "developer": "Miquel Angel Pavon Ribas",
      "targetDisease": "HPV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-02-23",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05334706"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women A",
          "nctId": "NCT05334706",
          "phase": "PHASE4",
          "population": "Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV",
          "comparator": "",
          "expectedReadout": "2026-12",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05334706",
        "url": "https://clinicaltrials.gov/study/NCT05334706",
        "date": "2026-02-23"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-measles-mumps-rubella-vaccine-mmr-laure-pittet-md-phd",
      "name": "Measles-Mumps-Rubella vaccine (MMR)",
      "developer": "Laure Pittet, MD-PhD",
      "targetDisease": "Measles / Mumps / Rubella",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2024-05-29",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05758532"
      ],
      "trialSubEntries": [
        {
          "trialName": "Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children",
          "nctId": "NCT05758532",
          "phase": "PHASE4",
          "population": "Respiratory Tract Infections, Infections, Allergy",
          "comparator": "",
          "expectedReadout": "2026-04",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-04 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05758532",
        "url": "https://clinicaltrials.gov/study/NCT05758532",
        "date": "2024-05-29"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "mmr-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-laiv-nasal-vaccine-is-chosen-as-a-model-viral-infection-universi",
      "name": "LAIV nasal vaccine is chosen as a model viral infection",
      "developer": "University of North Carolina, Chapel Hill",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-04-30",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06841913"
      ],
      "trialSubEntries": [
        {
          "trialName": "Woodsmoke Exposure, Influenza Infection, and Nasal Immunity",
          "nctId": "NCT06841913",
          "phase": "PHASE4",
          "population": "Smoke Exposure, Influenza",
          "comparator": "",
          "expectedReadout": "2028-12-31",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-12-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06841913",
        "url": "https://clinicaltrials.gov/study/NCT06841913",
        "date": "2026-04-30"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-9-valent-hpv-vaccine-cecolin-9-xiamen-innovax-biotech-co-ltd",
      "name": "9-valent HPV vaccine (Cecolin 9)",
      "developer": "Xiamen Innovax Biotech Co., Ltd",
      "targetDisease": "HPV",
      "platform": "Protein / subunit",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-06-25",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07668271"
      ],
      "trialSubEntries": [
        {
          "trialName": "Lot-to-Lot Consistency Clinical Trial of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vac",
          "nctId": "NCT07668271",
          "phase": "PHASE4",
          "population": "Infection by Human Papilloma Virus",
          "comparator": "",
          "expectedReadout": "2027-02-28",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-02-28 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07668271",
        "url": "https://clinicaltrials.gov/study/NCT07668271",
        "date": "2026-06-25"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-nonavalent-hpv-vaccine-university-of-british-columbia",
      "name": "Nonavalent HPV vaccine",
      "developer": "University of British Columbia",
      "targetDisease": "HPV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-02-05",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05495906"
      ],
      "trialSubEntries": [
        {
          "trialName": "A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV",
          "nctId": "NCT05495906",
          "phase": "PHASE4",
          "population": "HPV, Human Papilloma Virus, Human Immunodeficiency Virus",
          "comparator": "",
          "expectedReadout": "2026-08",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-08 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05495906",
        "url": "https://clinicaltrials.gov/study/NCT05495906",
        "date": "2026-02-05"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-serogroup-b-meningococal-vaccine-university-ghent",
      "name": "Serogroup B meningococal vaccine",
      "developer": "University Ghent",
      "targetDisease": "Meningococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-01-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06832514"
      ],
      "trialSubEntries": [
        {
          "trialName": "Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons",
          "nctId": "NCT06832514",
          "phase": "PHASE4",
          "population": "Meningococcal Meningitis, Serogroup B, Transgender Persons, Sex Differences in Immune Response",
          "comparator": "",
          "expectedReadout": "2026-07-31",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-07-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06832514",
        "url": "https://clinicaltrials.gov/study/NCT06832514",
        "date": "2026-01-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-trumenba-emory-university",
      "name": "Trumenba",
      "developer": "Emory University",
      "targetDisease": "Meningococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-12-22",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07197762"
      ],
      "trialSubEntries": [
        {
          "trialName": "MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults",
          "nctId": "NCT07197762",
          "phase": "PHASE4",
          "population": "Neisseria Meningitidis",
          "comparator": "",
          "expectedReadout": "2026-12",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07197762",
        "url": "https://clinicaltrials.gov/study/NCT07197762",
        "date": "2025-12-22"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "meningococcal-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-early-intervention-centre-hospitalier-universitaire-de-saint-eti",
      "name": "Early intervention",
      "developer": "Centre Hospitalier Universitaire de Saint Etienne",
      "targetDisease": "Pneumococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-03-30",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06822907"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults",
          "nctId": "NCT06822907",
          "phase": "PHASE4",
          "population": "Acute Febrile Illness, Pneumococcal Infections",
          "comparator": "",
          "expectedReadout": "2028-10-01",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-10-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06822907",
        "url": "https://clinicaltrials.gov/study/NCT06822907",
        "date": "2026-03-30"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-heplisav-b-injectable-product-2-dose-regimen-mercy-medical-cente",
      "name": "Heplisav-B Injectable Product, 2-dose regimen",
      "developer": "Mercy Medical Center",
      "targetDisease": "Hepatitis B",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2024-11-19",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04588077"
      ],
      "trialSubEntries": [
        {
          "trialName": "Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis",
          "nctId": "NCT04588077",
          "phase": "PHASE4",
          "population": "Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease",
          "comparator": "",
          "expectedReadout": "2028-12-01",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2028-12-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04588077",
        "url": "https://clinicaltrials.gov/study/NCT04588077",
        "date": "2024-11-19"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hepatitis-b-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-vaccine-administration-women-and-infants-hospital-of-rhode-islan",
      "name": "Vaccine administration",
      "developer": "Women and Infants Hospital of Rhode Island",
      "targetDisease": "Diphtheria / Tetanus / Pertussis",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2024-09-20",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06135636"
      ],
      "trialSubEntries": [
        {
          "trialName": "Assessing Interventions to Increase Tdap Acceptance for Non-birthing Partners in Pregnancy",
          "nctId": "NCT06135636",
          "phase": "PHASE4",
          "population": "Non-birthing Partner Vaccination in Pregnancy, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Vaccine Exposure During Pregnancy",
          "comparator": "",
          "expectedReadout": "2025-06-30",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-06-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06135636",
        "url": "https://clinicaltrials.gov/study/NCT06135636",
        "date": "2024-09-20"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "dtap-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-pcv15-university-of-oxford",
      "name": "PCV15",
      "developer": "University of Oxford",
      "targetDisease": "Pneumococcal disease",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-04-15",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT06731374"
      ],
      "trialSubEntries": [
        {
          "trialName": "Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15",
          "nctId": "NCT06731374",
          "phase": "PHASE4",
          "population": "Pneumococcal Disease, Pneumococcal Carriage",
          "comparator": "",
          "expectedReadout": "2025-12",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT06731374",
        "url": "https://clinicaltrials.gov/study/NCT06731374",
        "date": "2025-04-15"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "pcv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-tdap-vaccine-administration-canadian-immunization-research-netwo",
      "name": "RSV Vaccine",
      "developer": "Canadian Immunization Research Network",
      "targetDisease": "RSV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-06-16",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07097012"
      ],
      "trialSubEntries": [
        {
          "trialName": "Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy",
          "nctId": "NCT07097012",
          "phase": "PHASE4",
          "population": "RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Pregnancy",
          "comparator": "",
          "expectedReadout": "2026-07",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-07 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07097012",
        "url": "https://clinicaltrials.gov/study/NCT07097012",
        "date": "2026-06-16"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "rsv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-flumist-washington-university-school-of-medicine",
      "name": "FluMist",
      "developer": "Washington University School of Medicine",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-09-17",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07177417"
      ],
      "trialSubEntries": [
        {
          "trialName": "Characterizing the Human Airway Immune Response to FluMist Vaccination",
          "nctId": "NCT07177417",
          "phase": "PHASE4",
          "population": "Healthy Young Adults, Influenza Vaccines, Influenza Vaccine Response",
          "comparator": "",
          "expectedReadout": "2026-09",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-09 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07177417",
        "url": "https://clinicaltrials.gov/study/NCT07177417",
        "date": "2025-09-17"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-recombinant-zoster-vaccine-rzv-university-of-sao-paulo-general-h",
      "name": "Recombinant Zoster Vaccine (RZV)",
      "developer": "University of Sao Paulo General Hospital",
      "targetDisease": "Varicella / Zoster",
      "platform": "Protein / subunit",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-03-11",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT07280741"
      ],
      "trialSubEntries": [
        {
          "trialName": "Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators",
          "nctId": "NCT07280741",
          "phase": "PHASE4",
          "population": "Autoimmune Rheumatic Diseases",
          "comparator": "",
          "expectedReadout": "2027-07-30",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-07-30 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT07280741",
        "url": "https://clinicaltrials.gov/study/NCT07280741",
        "date": "2026-03-11"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "varicella-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-yellow-fever-vaccination-17-dd-biomanguinhos-oswaldo-cruz-founda",
      "name": "Yellow Fever vaccination (17 DD Biomanguinhos)",
      "developer": "Oswaldo Cruz Foundation",
      "targetDisease": "Yellow fever",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2018-07-30",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT03132311"
      ],
      "trialSubEntries": [
        {
          "trialName": "Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals",
          "nctId": "NCT03132311",
          "phase": "PHASE4",
          "population": "HIV Infections",
          "comparator": "",
          "expectedReadout": "2018-12",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2018-12 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT03132311",
        "url": "https://clinicaltrials.gov/study/NCT03132311",
        "date": "2018-07-30"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "yellow-fever-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-9-valent-hpv-vaccine-2-doses-alternate-timing-the-university-of-",
      "name": "9-valent HPV vaccine, 3 doses standard timing",
      "developer": "The University of Texas Medical Branch, Galveston",
      "targetDisease": "HPV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2025-10-06",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05672927"
      ],
      "trialSubEntries": [
        {
          "trialName": "Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)",
          "nctId": "NCT05672927",
          "phase": "PHASE4",
          "population": "Immunization, HPV Infection, Human Papillomavirus",
          "comparator": "",
          "expectedReadout": "2026-08",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2026-08 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05672927",
        "url": "https://clinicaltrials.gov/study/NCT05672927",
        "date": "2025-10-06"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-seasonal-influenza-vaccine-university-of-pennsylvania",
      "name": "Seasonal influenza vaccine",
      "developer": "University of Pennsylvania",
      "targetDisease": "Influenza",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2026-02-09",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT05108818"
      ],
      "trialSubEntries": [
        {
          "trialName": "Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults",
          "nctId": "NCT05108818",
          "phase": "PHASE4",
          "population": "Influenza, Human",
          "comparator": "",
          "expectedReadout": "2027-04-01",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2027-04-01 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT05108818",
        "url": "https://clinicaltrials.gov/study/NCT05108818",
        "date": "2026-02-09"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "influenza-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    },
    {
      "candidateId": "ctgov-gardasil9-miriam-elfstr-m",
      "name": "Gardasil9",
      "developer": "Miriam Elfström",
      "targetDisease": "HPV",
      "platform": "Biological (unspecified platform)",
      "currentStage": "phase_3",
      "jurisdictionStatus": [
        {
          "jurisdiction": "Multi / see trials",
          "status": "phase_3",
          "date": "2021-09-16",
          "dateType": "unknown",
          "notes": "Derived from ClinicalTrials.gov trial status/phase — not a company pipeline page claim"
        }
      ],
      "linkedTrials": [
        "NCT04910802"
      ],
      "trialSubEntries": [
        {
          "trialName": "Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden",
          "nctId": "NCT04910802",
          "phase": "PHASE4",
          "population": "HPV Infection, CIN 2/3, Cervical Cancer",
          "comparator": "",
          "expectedReadout": "2025-12-31",
          "status": "RECRUITING"
        }
      ],
      "expectedMilestone": "Primary completion (most advanced trial): 2025-12-31 (registry estimate)",
      "sourceType": "ClinicalTrials.gov API v2 (Tier 2) — trial-grouped candidate",
      "sourceCitation": {
        "label": "ClinicalTrials.gov NCT04910802",
        "url": "https://clinicaltrials.gov/study/NCT04910802",
        "date": "2021-09-16"
      },
      "lastCompanyUpdate": null,
      "lastVerified": "2026-07-10",
      "relatedVaccinePage": "hpv-vaccine.html",
      "note": "Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures."
    }
  ]
}